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Chronic periodontitis is a prevalent inflammatory disorder initiated by dental microbial 
plaque. Smoking is considered a major risk factor for chronic periodontitis and 
smokers are known to exhibit impaired treatment outcomes. 
 The overall aim of this work was to study clinical outcomes of active and 
supportive periodontal therapy in smokers and non-smokers with chronic periodontitis 
at patient, tooth, and site level. Moreover, to compare the periopathogenic microflora 
and inflammatory and bone remodeling markers in gingival crevicular fluid in smokers 
and non-smokers following therapy.    
 Eighty patients, 40 smokers and 40 non-smokers, with moderate to severe 
chronic periodontitis were included in this prospective cohort study and treated non-
surgically and surgically, and then followed-up in a supportive periodontal therapy 
program for 12 months. Smoking status was validated measuring serum cotinine levels 
at pre-treatment and 12 months following supportive periodontal therapy. Clinical 
measurements included full mouth recordings of clinical attachment level, probing 
depth, bleeding on probing, and plaque index at pre-treatment and following active and 
supportive periodontal therapy. At the same timepoints, subgingival plaque samples of 
20 subgingival periopathogenic bacterial species were analysed using checkerboard 
DNA–DNA hybridization. From a subsample including 25 smokers and 25 non-
smokers, 27 inflammatory and two bone gingival crevicular fluid markers were 
analysed using bead-based multiplex assays.  In all multilevel analyses probing depth 
≥5 mm with bleeding on probing was used as the primary outcome variable.  
 In smokers and non-smokers all patient level clinical parameters improved 
following non-surgical and surgical periodontal therapy. Only non-smokers showed a 
significant reduction in red complex species. At site-level, impaired outcome was 
observed in smokers and particularly at dental plaque positive sites (Study I). 
 Following 12 months of supportive therapy bleeding on probing, dental plaque 
positive sites, and probing depths increased slightly for both groups. Nevertheless, a 
negative effect of smoking was observed, in particular at maxillary single-rooted teeth. 
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At patient level, the multilevel analysis showed a suppressed variation in treatment 
outcome following supportive periodontal therapy in smokers (Study II).  
 Smokers demonstrated suppressed gingival crevicular fluid levels of several 
inflammatory markers and only non-smokers responded to periodontal therapy by 
altered marker profiles. An overall negative association was revealed between 
smoking and subgroups of markers at sites presenting ≥105 red complex periodontal 
microbial species (Study III).     
 In summary, smokers demonstrated unfavourable site-specific treatment 
outcomes compared with non-smokers, especially at plaque positive sites and at 
maxillary single-rooted teeth. Further, there seemed to be an immunosuppressive 
effect of smoking regulating the local inflammatory and bone remodeling response 
following periodontal therapy.  Collectively, the results indicate a site-specific tissue 
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1. INTRODUCTION  
1.1 Periodontitis 
The periodontium consisting of gingiva, periodontal ligament, cementum, and alveolar 
bone supports and protects the teeth in function. Gingivitis is a bacterial dental plaque 
induced minor inflammatory disorder of the gingiva and the prerequisite first stage of 
periodontal disease. When a gingivitis lesion advances to cause irreversible loss of the 
periodontal ligament and supporting bone, it has transformed into periodontal disease. 
Periodontal diseases, highly common and a major cause of tooth loss [1], have also 
been linked to conditions and systemic diseases including adverse pregnancy 
outcomes, diabetes mellitus, and cardiovascular, atherosclerotic and pulmonary 
diseases [2].  
 
1.1.1 Definition and classification of chronic periodontitis 
Periodontitis cases are characterized using clinical parameters including clinical 
attachment level (CAL), probing depth (PD), and bleeding on probing (BoP) and 
radiographic bone loss. Periodontal health is characterized by absence of these signs 
and symptoms [3]. However, the classification system of periodontal diseases is 
essentialistic, based on the aetiology of the disease [4]. Out of six destructive 
periodontal diseases, chronic periodontitis is the most prevalent and a major cause of 
tooth loss [5]. Assessment of the severity of periodontitis is based on the extent of 
attachment loss, 1-2 mm considered mild, 3-4 mm moderate, and ≥5 mm severe 
periodontitis. The cut-off level between aggressive and chronic periodontitis is not 
distinct and based on clinical features. Unlike aggressive periodontitis, chronic 
periodontitis lesions are generally observed in adults with no specific familiar 
aggregation and characterized by a continuous loss of periodontal tissues associated 
with subgingival plaque, calculus, and individual risk factors [6, 7]. The progression of 
chronic periodontitis seems to be continuous with slow to moderate bursts of tissue 





1.1.2 Epidemiology  
Periodontal diseases are characterized using surrogate parameters including CAL, PD, 
and BoP on a site and tooth level [3]. Thresholds defining periodontitis cases are 
critical to assess and compare epidemiological and patient related data. Case 
definitions presented by the American Academy of Periodontology (AAP) [10] and the 
European Federation of Periodontology (EFP) [11] represent present standard in clinical 
and epidemiological research.  
Prevalence of periodontitis varies among populations [7]. Severe forms, 
however, seem to affect around 10% of diverse populations [12-14] with a global age 
standardized prevalence of 11% [15]. Comprehensive epidemiological data has been 
gathered from the National Health and Nutrition Examination Survey (NHANES) in 
the United States. In 2009-2012 and based on EFP definition, an estimated prevalence 
of severe periodontitis in the US adults older than 30 years approximates 12% for 
severe and 66% for incipient periodontitis [14]. Estimates based on the AAP definition 
approximate 9% for severe and 37% for mild and moderate periodontitis. Periodontitis 
is cumulative and the incidence increases gradually from age 30 to 80 years to peak at 
age 38 years [15]. Increasing life expectancy may increase the burden of periodontitis 
and the prevalence of non-severe periodontitis in US adults 65 years and older to 64% 
using the AAP case definition [16]. Risk factors including smoking, educational and 
socioeconomic status, diabetes mellitus, health care availability, and oral hygiene 
habits [17] may also contribute to an increase in the burden of periodontitis [3]. In 
particular, smoking appears strongly associated with increased prevalence and severity 




Figure 1. Prevalence of severe and non-severe periodontitis in smokers and non-smokers 
2016, based on data from NHANES. 
 
1.1.3 Aetiology 
As bacterial dental plaque accumulates onto the tooth surface forming structured 
communities defined as dental biofilm [20], intractable biofilm formations provoke 
inflammatory processes in the subjacent gingiva to induce gingivitis [21]. A further 
increase in biomass and microbial complexity may disturb established tissue 
homeostasis and induce a destructive inflammatory process in the susceptible host [22]. 
Failing resolution or imbalance may further advance the inflammatory process into 
periodontitis – irreversible destruction of the periodontal attachment accompanied by 
migration and proliferation of the gingival sulcular epithelium onto the root surface 
[23]. Resulting deepening of the gingival sulcus establishes a periodontal pocket that 
provides protection and an anaerobic environment for bacterial species within the 
biofilm and growth of putative pathogenic species. The gingival tissues facing the 
biofilm provide a steady influx of molecules and immune cells within an inflammatory 
exudate known as gingival crevicular fluid (GCF). This new econiche including GCF 
as principle nutritional source permits additional quantitative and qualitative variations 
within the biofilm [24]. Gram-negative bacteria associated with periodontitis include 
Porphyromonas gingivalis, Tannerella forsythia, Treponema Denticola, and 
Aggregatibacter actinomycemtemcomitans [25, 26]. These bacterial species comprise a 
fraction of the total biomass [22]. Recent concept suggests, however, that only few 
bacterial species play a role as “keystone” periopathogenic bacteria [27]. “Keystone” 
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pathogens indirectly provoke periodontitis by transforming the normally symbiotic 
microbiota into a dysbiotic one which in turn activates the host immune response 
responsible for associated irreversible tissue damage [28]. P. gingivalis has in low 
abundance a potential to transform biofilms into a dysbiotic state and is hence 
recognized as a “keystone” pathogen [29]. 
Dental biofilm activates the innate and adaptive immunity in highly complex 
events, involving recruitment of neutrophils, activation of lymphocytes, and activation 
of the complement system [30]. Cytokines, soluble small molecules responsible for 
crosstalk between immune cells and guidance of inflammatory responses, adjust the 
host responses to periodontal pathogens with up- and downregulation of genes [31]. The 
immune-inflammatory response intends to protect the host from infection and return 
the tissues to homeostasis. However, chronic stress may influence the inflammatory 
response and result in non-resolution of inflammation and periodontal tissue 
destruction. Re-establishing tissue homeostasis following infection appears to be an 
active coordinated process involving several biochemical pathways. Host factors, 
including immune components and resident cells, contribute by producing markers to 
the resolution of the inflammatory processes [30]. 
The magnitude of the host response depends on genetics and environmental 
risk factors. Principally, periodontal tissue destruction is based on altered 
inflammatory response to subgingival biofilm [32]. The genetic component for a 
predisposition to chronic periodontitis is considered polygenetic and estimated to 
constitute 50% of the total risk for chronic periodontitis [33, 34]. Other risk factors 
known to increase susceptibility to periodontal disease may be modifiable such as 
cigarette smoking, stress, obesity, and diabetes mellitus [35]. Being male is also 
considered a modifiable risk factor as gender differences in lifestyle rather than genetic 
factors appear to predispose to periodontitis [35]. Cigarette smoking is also considered a 
causal factor for chronic periodontitis [36] and evaluation of clinical consequences for 





Figure 2. Anatomy of the periodontium in a) periodontal health and b) periodontal disease 
 
1.2 Periodontal therapy 
The ultimate goal in periodontal therapy is to prevent loss of periodontal support and 
tooth loss by self-performed plaque control creating equilibrium between plaque and 
host inflammatory responses. Lost periodontal tissues have a potential for 
regeneration. At present, however, a realistic goal for periodontal therapy is to control 
and eliminate periodontal disease by tissue repair.  
1.2.1 Historical view 
Oral hygiene and removal of calculus have been advocated in ancient civilizations and 
surgical removal of diseased periodontal tissues was described already in the 18th 
century [37]. Later, development of microscope, local anesthesia, and radiography 
contribute to a scientific understanding of a microbial aetiology of periodontal diseases 
[38]. Evidence based periodontal therapy developed in the second half of the 20th 
century following demonstration of bacterial dental plaque as an etiological factor in 
periodontal disease [39]. The principle of removing dental biofilm by self-performed 
oral hygiene and mechanical instrumentation developed non-surgical and surgical 
techniques to access subgingival plaque and not primarily surgical removal of diseased 
tissues. Longitudinal studies demonstrated the critical importance of high standard 
self-performed oral hygiene following periodontal therapy [40, 41] and minimally 
resective surgical approaches became the gold standard [42]. Therapeutic techniques 
were developed to regenerate lost periodontal tissues [43, 44] and paved the way for new 
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regenerative therapeutically approaches [45]. Documentation of pathogenic bacterial 
species in subgingival dental plaque led up to the specific plaque hypothesis 
suggesting a limited number of microbial species linked to the pathogenesis of 
periodontitis and a subsequent growth of local and systemic antimicrobial therapies 
[46]. However, as clinical trials failed to identify bacterial dental plaque as a prognostic 
factor for periodontal attachment loss [47, 48] and patient related risk factors were 
associated with periodontal disease [49], the ecological plaque hypothesis emerged. 
This hypothesis introduced an effect of ecologic stress on enrichment of bacterial 
species [50]. Persistent inflammation was associated with disease progression [51, 52] and 
anti-inflammatory and host modulation approaches addressed to resolve inflammation 
were introduced as an adjunct to the mechanical plaque control [53]. The 
“keystone” pathogen hypothesis introduced bacterial species within subgingival 
biofilm to cause a dysbiotic biofilm triggering periodontal tissue destruction [27]. The 
simple concept that periodontal disease is caused solely by bacterial dental plaque 
appears no longer valid and a multifactorial causation has been documented and 
targeted [35, 54]. Therefore, supplement of mediators downregulating the inflammatory 
processes might be promising in the treatment of chronic periodontitis.   
1.2.2 Treatment of chronic periodontitis 
Periodontal therapy constitutes a number of interventions considering the 
multifactorial aetiology of chronic periodontitis. Initially, patient related risk factors 
related to systemic health should be identified [55]. Risk of infections, endocarditis, 
bleeding disorders, and therapeutic efforts to modulate host-responses must be 
considered prior to active therapy [56, 57]. Counselling for smoking cessation and 
regulation of blood glucose, stress, diet, and weight should be integrated parts of active 
periodontal therapy [58-60]. Moreover, systemic medications and resolution-phase lipid 
mediators have the potential to downregulate and modulate inflammatory host 
responses [61]. However, this new treatment concept is not yet integrated in current 
systematic periodontal therapy [60].   
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1.2.2.1 Non-surgical therapy 
The hygiene phase of non-surgical periodontal therapy intends to establish a balance 
between bacterial insult and the host response through reducing the presence of 
bacterial dental plaque or biofilm. High standard plaque control appears pivotal to 
prevent gingivitis and maintain a healthy dentition [62, 63]. Prevention of gingivitis also 
prevents periodontitis [23]. Self-performed oral hygiene is the mainstay to prevent 
chronic periodontitis; a single manual tooth brushing exercise may reduce mean 
plaque scores up to 42% [64]. However, professional plaque control without instruction 
in self-performed oral hygiene appears of limited value [65] while repeated oral hygiene 
instruction may improve self-performed plaque control [64]. The duration of tooth-
brushing correlates inversely with the presence of residual plaque and effective oral 
hygiene routines require careful selection of personal oral hygiene aides [66]. In 
perspective, power toothbrushes appear to increase the efficacy of plaque removal by 
7-17% over manual toothbrushes [67], whereas interproximal tooth surfaces are more 
efficiently cleaned using interdental brushes [68]. 
 As chronic periodontitis advances, the relative efficacy of high standard oral 
hygiene becomes reduced [69]. Mechanical instrumentation of the periodontal pocket 
then becomes a prerequisite to arrest the periodontal infection by removal of 
subgingival plaque and calculus from the root surfaces and the subgingival econiche 
[70]. Nevertheless, removal of plaque and calculus remains demanding and subgingival 
debridement may result in varying presence of residual calculus [71, 72] depending PD, 
subgingival access, tooth type and surface, furcation involvement, local retentive 
factors, and operator skills [73-77]. Hand instruments, sonic or ultrasonic scalers, and 
Er:Yag lasers are all used for supra- and subgingival periodontal instrumentation. 
There seems to be no superior effectiveness between any of these approaches in 
treatment of chronic periodontitis [78].  
 Part of an ongoing debate concerns preferred staging of non-surgical 
periodontal therapy whether to use a quadrant or sextant sequenced approach at 1-2 
week intervals or a full-mouth approach. The principle of a full-mouth approach is to 
perform comprehensive periodontal instrumentation and elimination of 
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periopathogenic bacteria from other oral niches within 24 hours [79]. A meta-analysis 
shows modest clinical benefits of the full-mouth approach over sequenced quadrant-
wise instrumentation [80]. Nevertheless, these various approaches are considered 
comparable options in the non-surgical therapy of chronic periodontitis [81]. The choice 
of protocol should rather be based on practical considerations related to time, patient 
preference, and clinical work load [82]. Healing response is usually assessed within 1-2 
months following non-surgical therapy [83] and for patients with mild to moderate 
periodontitis, non-surgical treatment appears sufficient to maintain a stable attachment 
[84].  
1.2.2.2 Surgical therapy 
Chronic periodontitis patients enter a surgical phase of periodontal therapy principally 
to facilitate removal of subgingival plaque and calculus under visual inspection in sites 
that do not respond to non-surgical therapy and to prepare access for effective oral 
hygiene measures [84]. Open debridement surgery may reduce PDs promoting long-
term preservation of the periodontium and thereby improving the prognosis of the 
tooth [85, 86]. Various access flap techniques have been developed. A systematic review 
indicated a cut-off PD value of 6 mm for surgical debridement aiming to reduce PD 
and gain clinical attachment. Open debridement in sites with PDs <4 mm may result in 
attachment loss [84]. The gingivectomy technique intends to remove the soft-tissue wall 
of the periodontal pocket in an apical direction creating access to the root surface for 
instrumentation and postsurgery oral hygiene [87]. The technique might not be 
performed at teeth in absence of attached keratinized gingiva and in intraosseous 
defects and thus appears more appropriate in cases with gingival enlargement [88].  
Access flaps in combination with regenerative procedures aim to restore lost 
periodontal tissues [45]. Though current regenerative techniques are operator sensitive 
and predictability is limited to certain low-risk profile patients, promising advances 
may shift the paradigm of periodontal therapy from repair to regeneration. Guided 
tissue regeneration procedures using barrier membranes intend to preclude epithelial 
and connective tissue from occupying the wound area thus allowing periodontal 
ligament cells and alveolar bone to restore and regenerate new supporting tissues. 
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Other regenerative procedures include application of signalling molecules such as 
enamel matrix derivatives, platelet-derived growth factors, and bone morphogenetic 
proteins [89]. Further, several types of mesenchyme-derived cells with a potential to 
differentiate into periodontal tissue forming phenotypes have been investigated at a 
preclinical level [90]. Contextualized within periodontal regeneration, tissue 
engineering involves implantation of a scaffold incorporated with progenitor cells 
directly into a periodontal defect [91]. However, to develop the regenerative potential of 
the periodontal ligament is demanding and challenges remain before incorporated in a 
clinical setting [92]. 
1.2.2.3 Supportive therapy  
Supportive periodontal therapy (SPT) is designed to maintain a healthy dentition to 
prevent or minimize disease recurrence or tooth loss over the lifespan of the patient [93-
96]. A well-organized supportive periodontal therapy program may maintain 
periodontal health even in severe chronic periodontitis patients [94]. Absence of 
supportive therapy may jeopardize the successful outcomes of the non-surgical and 
surgical treatment [40, 97, 98].  
 Supportive periodontal therapy should consist of regular recall appointments 
including an update of systemic and oral health, examination of soft tissues and teeth, 
evaluation of self-performed oral hygiene, re-motivation, and complete plaque 
removal [99]. High standard self-performed oral hygiene and attendance to scheduled 
supportive periodontal therapy are critical [100-103]. Longitudinal studies have shown 
that favourable outcomes following active periodontal therapy may be lost due to poor 
compliance [94, 104]. Risk factors for tooth loss and recurrence of chronic periodontitis 
during supportive periodontal therapy are patient-, tooth-, and site-related factors 
including smoking, systemic disorders, compliance, furcation involvements, residual 
PDs, and BoP [52, 101, 105-107]. These factors may categorize patients based on risk 
profiles for future disease progression [108] and create a rationale for individually 
tailored supportive periodontal therapy [109]. However, following completion of active 
therapy, only a few predictive factors including smoking, plaque, and compliance are 
left to be modulated throughout supportive periodontal therapy. If the standard of daily 
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oral hygiene is inadequate and smoking cessation has failed, a more frequent recall 
interval appears necessary [110]. Based on previous studies, 3-month recall intervals are 
recommended for patients at risk [75, 111-113]. Only 26-77% of periodontal patients seem 
to fully comply with prescribed recall protocols [110]. In particular patients at high risk 
seem to have inconsistent compliance [114].  
                                      
Figure 3. Modifiable predictive factors determining the outcome of supportive periodontal 
therapy 
 
1.2.2.4 Antimicrobial therapy 
The oral microflora is ecologically diverse as it includes at least 350 cultivable species. 
Culture-independent molecular approaches have identified about 1,200 different types 
of microbes that can inhabit the oral cavity [Human Oral Microbiome Database 
(http://www.homd.org)]. Development of biofilm may shelter bacteria from immune 
responses and antibiotic therapy [115]. Locally delivered antimicrobials are within 
minutes washed away from the periodontal pocket and thus may not reach relevant 
thresholds or substantivity [116]. Clinically relevant effects of the adjunctive use of 
locally delivered antibiotics in non-surgical therapy have been questioned as not being 
convincingly documented [117]. Nevertheless, a benefit of locally delivered devices has 
been estimated to 0.4 mm in PD reduction and 0.3 mm in CAL gain for deep 
periodontal sites [118]. A recent systematic review evaluating the use of local and 












surgical periodontal therapy, found an additional PD reduction of 0.81 mm and CAL 
gain of 0.91 mm for locally delivered antimicrobials at sites with deep baseline PD 
(PD ≥ 5mm). The review failed to detect similar adjunctive effects of systemic 
antimicrobial therapy [119]. 
 Some virulent bacterial strains are thought to penetrate the epithelial lining of 
the periodontal pocket [120]. As these pathogens appear inaccessible to instrumentation, 
a rationale for the use of systemic antibiotics emerges [116]. Positive effects of systemic 
antibiotics as adjunct to routine periodontal debridement have been shown for patients 
with inadequate response towards conventional non-surgical periodontal therapy, 
recurrent periodontitis, periodontal abscesses, and patients experiencing 
lymphadenopathy and fever post-therapy [118]. Preferred protocol appears to first 
mechanically disrupt any microbial reservoirs to make the residual contaminants more 
vulnerable to the antibiotic [121]. Nevertheless, it remains uncertain which patients 
should be targeted and what drugs and doses should be used for this approach.  
Systemic antimicrobial therapy on periodontal indications should be 
contextualized in a growing concern of bacterial resistance to antibiotics and drug 
induced adverse effects [118]. Less stringent prescription routines and increasing non-
supervised consumption of antibiotics seem to decrease bacterial susceptibility as well 
as increasing the possibility of drug resistant pathogens [122, 123]. In perspective, 
Scandinavian countries exercise restricted use of antibiotics in periodontal therapy 
compared with Southern Europe, US, and South America [124]. As periodontal 
pathogens differ in sensitivity towards antibiotics, microbiological testing may 
possibly increase the clinical efficacy by primarily targeting susceptible species [125]. 
However, the clinical relevance of microbiological testing has been questioned in 
studies obtaining excellent clinical outcomes following therapy without preceding 
microbiological testing [126].  
1.3 Periodontal wound healing  
Wound healing is the dynamic biological interplay between tissues, local and 
infiltrating cells, and signalling molecules released into the cellular environment. In 
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general, periodontal wound healing does not result in regeneration, complete 
functional and structural restoration of lost or injured tissues, but rather by scar 
formation [127]. Scar tissue represents a functional compromise which never exceeds 
80% strength compared with the pristine tissue [128, 129]. Healing of periodontitis lesions 
occurs in complex settings with infected and inflamed periodontal tissues interacting 
with the tooth in a transgingival position displaying vascular soft tissue and non-
vascular rigid wound margins. Plaque control is critical as infection may impair the 
healing process [130]. Despite the infectious environment, the oral mucosa tends to heal 
rapidly and with limited scar formation compared with cutaneous wounds [131]. 
Detailed mechanisms are not fully elucidated; however, components in saliva may be 
critical determinants of oral tissue homeostasis [132]. 
1.3.1. Stages of wound healing/repair 
Periodontal wound healing may be conceptualized into integrated phases generally 
paralleling that in cutaneous wounds [133, 134]. Briefly, platelets exposed to extracellular 
matrix and collagen immediately form a fibrin clot. Activated platelets release 
cytokines, growth factors, and clotting factors initiating haemostasis, wound 
contraction, and formation of a fibrin-fibronectin mesh. As the fibrin clot in turn is 
infiltrated by neutrophils, monocytes/macrophages, fibroblasts, and endothelial cells, 
the haemostatic phase gradually progresses into an inflammatory phase [134]. 
Endothelial cells control the recruitment of cells in surrounding tissues, and within 1-
24 hours neutrophils and monocytes appear. Neutrophils play a critical role cleaning 
the wound of tissue debris, effete-blood-cells, and destroying invading bacteria 
through phagocytosis, release of oxygen radicals, and activation of the complement 
system [135]. While the number of neutrophils peaks within 24-48 hours, the number of 
macrophages-continues to increase [135]. Macrophagessderived from monocytes supply 
the wound with a continuous flow of cytokines and growth factors transforming the 
fibrin clot into granulation tissue [136], a highly vascularized immature tissue 
constituting extracellular matrix and fibroblasts.  
 In the proliferative phase, anabolic processes raise metabolic demands met by 
increased vascularity. Extracellular matrix factors and a variety of growth and matrix 
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factors stimulate migration and proliferation of endothelial cells from blood vessels 
and circulating endothelial progenitors [137] and thereby angiogenesis. One to 2 days 
post-injury, epithelial cells originating from the wound margins, separate from their 
basement membrane and migrate through degraded collagen and extracellular matrix 
by integrin receptors [136]. Following the migration and phenotypic transformation of 
the cells, attachment to the basement membrane is restored [138]. Keratinization of the 
epithelial cells is induced by tissue resources residing in the periodontal ligament and 
appears controlled by the sulcular environment [127]. Approximately 7 days post-injury, 
fibroblasts originating from the gingival connective tissue and the periodontal ligament 
populate the extracellular matrix to dominate the wound. Attached in a fibrin matrix, 
the fibroblasts mature into various phenotypes to produce diverse collagen species [139]. 
During the following remodeling phase, collagen is clustered into bundles by 
increasing cross-linking [140]. Maturation of the tissue continues slowly and may last 
for months, even years, regulated by factors released by macrophages, epidermal cells, 
endothelial cells, and fibroblasts [141]. 
1.3.2 Wound healing following periodontal treatment 
Subgingival debridement inadvertently injures the sulcular and junctional epithelium. 
However, strict removal of these tissues is not advocated [142]. The resulting wound is 
left to heal by secondary intention and pending the magnitude of induced injury, 
healing by formation of a long junctional and sulcular epithelium is established within 
1-2 weeks [143]. The junctional epithelium connects to the root surface through 
hemidesmosomes from the internal basal lamina.  
  Resective periodontal surgery including gingivectomy may generate larger 
connective tissue wounds readily exposed to oral bacteria and left to heal by secondary 
intention [87]. A fibrin clot will immediately cover the wound and within few days 
epithelial migration is initiated from the wound margins. The exposed wound may 
become epithelized within 1 week. Keratinization and reformation of rete-pegs in 
attached gingiva will re-establish within 2 weeks, tissue maturation appreciable within 
5-6 weeks [144].  
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Using flap surgery techniques, ideally surgical wounds are left to heal by 
primary intention, the wound margins approximated and stabilized by sutures. A 
stabilized fibrin clot secures unimpeded absorption of plasma proteins onto the root 
surface and wound maturation into a connective attachment rather than epithelial down 
growth over exposed gingival tissues [133]. Careful tissue management and stable 
readaption of the wound-margins appear critical to provide an epithelial attachment 
within 10-12 days and re-vascularization of the wound [145]. Thus, a new connective 
tissue attachment may be established following flap surgery.  
Tissue resources sequestered in the periodontal ligament have the potential to 
support a connective tissue attachment with collagen fibers attaching to the root 
surface [127, 146]. Regenerative periodontal therapy may support formation of new 
alveolar bone, root cementum, and a functionally oriented periodontal ligament. It 
appears that regeneration can only be achieved if both the gingival epithelium and 
connective tissue are prevented from repopulating the surgically prepared wound, 
allowing cells from the periodontal ligament and alveolar base to recruit the defect [45]. 
Wound closure for healing by primary intention, space provision, and wound stability 
appear critical bioclinical factors to achieve these objectives [147]. 
1.4 Chronic periodontitis and smoking 
Smoking, the inhalation of smoke from burning tobacco, constitutes approximately 
5000 different molecules inhaled through the oral and nasal cavity before the 
vaporized gases absorb in the lungs [148]. Worldwide, around 1.3 billion people smoke 
and the smoking epidemic is projected to increase linked to population growth in 
developing countries [149]. Smoking is considered a principal risk factor for a number 
of chronic diseases including cancer and pulmonary and cardiovascular diseases; in 
2010 costing about 5 million lives globally with projected more than 10 million lives 
yearly a few decades ahead. Relatively few of the about 10% of adolescent women and 
50% of adolescent men starting to smoke, will succeed to abstain due to physical 
addiction to smoking products and psychological addiction to smoking habits [150]. 
Extensive smoking cessation occurs in some high-income countries; in Norway for 
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example, the prevalence of smokers has been reduced by 30% from 43% to 13% 
within a decade [151].  
Smoking is recognized as a major patient related risk factor for chronic 
periodontitis. Evidence for the association between smoking and chronic periodontitis 
has been demonstrated in diverse populations [152]. Smokers tend to present with 
increased tooth loss, aggravated bone and attachment loss, and deeper periodontal 
pockets compared with non-smokers [18, 19, 153-155]. The most comprehensive analysis 
based on the NHANES III Study suggests approximately 50% of periodontitis cases 
being smokers [18]. Moreover, smokers have approximately four times greater risk of 
presenting with chronic periodontitis compared with non-smokers. The susceptibility 
to periodontitis progression appears dose-related with higher prevalence and increased 
loss of teeth and periodontal attachment in heavy smokers [156]. Based on multivariable 
logistic regression analysis in a South Brazilian population, attribution of smoking to 
attachment loss was estimated to 38% for heavy smokers and 16% for moderate 
smokers. Smoking impact was calculated by multiplying the number of days smoking 
with the number of cigarettes consumed per day divided by 20 (one pack of cigarettes) 
with a cut-off value >7300 packs for heavy smokers and 2735-7300 for moderate 
smokers. Compared with non-smokers, the odds ratio (OR) for heavy smokers to 
present with more sites with clinical attachment loss >5 mm was 3.6. The 
corresponding OR for moderate smokers was 2.0 [153]. In a prospective European study 
smoking in excess of 15 cigarettes per day was associated with >2 times higher risk of 
tooth loss in women and >3 times higher risk of tooth loss in men [155]. An Australian 
study defining heavy smoking as greater than 15 packyears (number of packs of 
cigarettes smoked per day multiplied with number of years smoked), showed that 
almost half the heavy smokers were periodontitis cases and less than one-fifth were 
never-smokers [154]. Compared with a smoking exposure of less than 20 packyears, 
heavy smoking in an adult US population revealed an OR for periodontitis of 2.1 
according to the EFP and 2.4 based on the AAP definition [157].  
The association between chronic periodontitis and smoking seems not to be 
explained by differences in oral hygiene standards among smokers and non-smokers 
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[158]. Further, the association between chronic periodontitis and smoking is weakened 
over time following smoking cessation [18, 19, 159]. Longitudinal studies show 
comparable CAL in young smokers and non-smokers 6 years following smoking 
cessation. After 10-20 years cessation, former smokers tend to show less bone loss 
than smokers and approach the level of never smokers relative to tooth loss [155, 160, 161]. 
A causal association between smoking and tooth loss and smoking and chronic 
periodontitis is highly likely, with the strength of the association depending on 
chronicity and frequency of exposure [36, 162]. 
 
Figure 4. Clinical picture of a smoking severe chronic periodontitis case characterized by 
gingival recessions, minor clinical sign of gingival inflammation, and staining of the teeth. 
 
1.5 Smokers responses to periodontal therapy 
Except for smoking cessation counselling, similar procedures are employed in treating 
chronic periodontitis in smokers and non-smokers. Non-surgical therapy by 
mechanical disruption of plaque is considered routine, even though less favourable 
therapeutic outcomes in smokers have repeatedly been documented [163-165]. A series of 
clinical studies in Sweden during the 1980s and 1990s initiated the systematic 
investigation of the effects of smoking on periodontal therapy [166-168], paving the way 
for prospective studies employing single-level statistics to compare means of PD, 
bleeding on probing, plaque, and periodontal pathogen levels in smokers and non-
smokers following non-surgical periodontal therapy. PD considered the primary 
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outcome measure showed 0.2-0.9 mm less reduction in smokers with similar efficacy 
for one-stage full-mouth debridement and conventional quadrant-wide approaches [169-
174]. Although these means appear small, PD reduction in the smoking populations is of 
clinical relevance. In favour of non-smokers, a meta-analysis of the influence of 
smoking on non-surgical therapy demonstrated a mean PD difference of 0.1 mm and 
for sites with initial probing depth >5 mm, 0.4 mm. No significant differences were 
documented for CAL and BI [164]. Prospective studies using multilevel statistics 
confirm the impaired outcomes in smokers following non-surgical therapy, especially 
for plaque positive sites, multi-rooted teeth, and deeper periodontal pockets [173, 175]. 
The probability of a 6-mm periodontal pocket to close (≤4 mm) has been estimated to 
31% at single-rooted and 51% at multi-rooted teeth in smokers compared with 43% 
and 64%, respectively, for non-smokers. Corresponding estimates for 7-mm pockets 
were 12% and 25% in smokers and 20% and 36 % in non-smokers [175]. 
Smokers affected by chronic periodontitis appear to harbour increased levels of 
putative periopathogenic bacteria [176, 177]. Investigations have reported a smaller 
reduction of periodontal pathogens in smokers following non-surgical therapy. 
Prospective studies suggest that P. gingivalis, T. forsythia and T. denticola may be 
more prevalent in smokers than in non-smokers following non-surgical therapy [62, 172, 
178]. A reduced response to antimicrobial treatment in smokers is supported by cross-
sectional and retrospective studies [176, 179]. In contrast, with an objective validation of 
smoking status, others have found similar reductions of periodontal pathogens in 
smokers and non-smokers following periodontal therapy [180]. Despite aggravated 
periodontal pathogens, adjunctive use of systemic and local antibiotics in conjunction 
with non-surgical periodontal therapy does not appear to advance PD reduction or 
CAL gain in smokers compared with non-smokers [181].  
Non-surgical therapy in non-smoking chronic periodontitis patients is 
associated with reduced systemic inflammation, mirrored in reduction of systemic 
levels of c-reactive proteins and other inflammatory mediators [182, 183]. In contrast, 
smokers appear to have a suppressed antibody response to periodontal pathogens [180] 
with no significant reduction in c-reactive proteins (21 days) following non-surgical 
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therapy [184]. As GCF appears a relevant source of biomarkers of wound healing, 
prospective clinical studies have observed impaired outcomes of non-surgical therapy 
in smokers measured as local inflammatory responses in GCF. Following non-surgical 
periodontal therapy, altered treatment responses in smokers have been demonstrated 
for pro-inflammatory cytokines [interleukin (IL)-1β, tumor necrosis factor (TNF)-α, 
chemokines (IL-8), and matrix metalloproteinase (MMP)-8] [185-188]. 
As smokers present with more severe chronic periodontitis and experience 
reduced response to non-surgical therapy, there may be an increased need for re-
treatment. A retrospective study comparing sites with PD ≥6 mm before and after non-
surgical therapy found 30% remaining sites among smokers compared with 15% for 
non-smokers. At patient level, the possibility of requiring further treatment was 43% 
for smokers and 12% for non-smokers [189]. For both smokers and non-smokers, re-
instrumentation following non-surgical therapy reduced  pocket depth (PD ≤4 mm) in 
58% of sites presenting PD ≥5 mm and 12% of PD >6 mm [190]. For smokers, furcation 
involvement I and II appear particularly challenging by only 24% probability of 
improvement compared with non-smokers following re-instrumentation [191].  
In patients with advanced periodontal disease, periodontal surgery aims to 
achieve pocket closure and restore periodontal health. Current smokers may be 
candidates for periodontal surgery, though the benefit from PD reduction is estimated 
to only 50-75% of that accomplished in non-smokers [192]. The magnitude of 
differences between smokers and non-smokers correlates to responses to non-surgical 
therapy. A meta-analysis has quantified the outcomes in smokers following surgical 
therapy to be reduced 0.4 mm for PD and CAL compared with non-smokers [193]. 
Following flap surgery, furcation involvement I and II improved in 3% of degree I 
sites in smokers compared to 27% in non-smokers and smokers having 50% of the 
attachment gain of non-smokers [194].  
No evidence supports the use of systemic antibiotic as adjuncts to surgical 
periodontal therapy in smokers [119, 195], though more favourable outcomes have been 
reported when using systemic antibiotic following regenerative treatment of furcation 
II defects [196]. Overall, smoking seems to impair periodontal wound healing in a dose-
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dependent manner with negative effects on bone and attachment gain [197, 198]. A meta-
analysis estimated the negative effect of smoking on bone gain in intrabony pockets to 
2.1 mm[197]. Following guided tissue regeneration, a retrospective study found as much 
as 3.1 mm reduced attachment gain in intrabony pockets in smokers [199]. Regarding 
furcations, remaining defects were observed in 63% of smokers and 14% of non-
smokers 24 months following surgery [200]. 
Smokers enrolled in a maintenance program receiving regular supportive 
periodontal treatment show more tooth and bone loss and less PD reduction and CAL 
gain compared with non-smokers [86, 201-204]. As many as 90% of patients with recurrent 
chronic periodontitis are smokers [204] and heavy smoking is a risk factor for disease 
progression during supportive periodontal therapy [86]. The outcomes of periodontal 
therapy are associated with smoking consumption [201] and smoking cessation may 
improve the treatment response and reduce the risk of relapse of active disease during 





2. RATIONALE FOR DESIGNING THE STUDY   
Clinical parameters related to chronic periodontitis include PD, CAL, BoP, plaque 
accumulation, and GCF volume. By recording these parameters, previous periodontal 
destruction, ongoing disease and prediction of disease progression may be monitored 
[208]. Clinical parameters implemented in the diagnosis of chronic periodontitis are 
essential for treatment planning and to evaluate treatment outcomes. Smokers express 
clinical parameters differently than non-smokers with reduced BoP and GCF volume 
means [209, 210], and increased PD and CAL means [152]. Moreover, periodontal healing 
appears impaired in smokers following both active and supportive periodontal therapy. 
Smoking seems to affect active periodontal therapy through local and systemic 
pathways and impairs the inflammatory and the proliferative phase of periodontal 
wound healing [164, 178, 188]. Nevertheless, the aetiology behind the impaired healing 
response in smokers following active periodontal therapy is not clear.  
 When patients enter supportive periodontal therapy, acute periodontal wound 
healing has resolved and an overlapping phase of remodeling is initiated. Remodeling 
of the wound continues and the architecture gradually approaches normal [211]. The 
remodeling phase may continue for years and is responsible for wound contraction and 
scar formation. However, little is known about how smoking influences tissue 
maturation during supportive periodontal therapy.  
 Most studies have documented negative effects of smoking on periodontal 
therapies at a patient level [106]. To report patient-level treatment outcomes is 
appropriate as smoking represents a major patient-related risk factor for chronic 
periodontitis. Patient-level analysis provides limited evidence of associations between 
residual pockets and disease progression [86, 110]. Site or tooth as the unit of analysis is 
preferred in clinical studies. By averaging data, clinical relevant information is lost for 
both patient- or site-level analysis [212]. Teeth and sites share the same patient-related 
risk factors and are not independent units. Periodontal parameters are clustered in 
hierarchical structures within patients, in teeth within patients, and in sites within 
teeth. Furthermore, in follow-up studies, sites, teeth, and patients will be clustered 
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within repeated measures. Single level statistics will therefore not reflect the nature 
and dynamic diversity of site-specific responses to periodontal therapy [212].  
 Multilevel statistics with the site as the unit of analysis may provide new 
insights into mechanisms of wound healing in smokers. Table 1 depicts the numbers of 
prospective studies over the last 30 years reporting the effect of smoking on treatment 
outcomes following active and supportive periodontal therapy. The literature screening 
shows that only two prospective studies have investigated the effect of smoking on 
non-surgical therapy using multilevel approaches but without objectively validating 
smoking status. As smoking modifies both local and systemic etiological risk factors, 
site-specific treatment responses in smokers may show altered site-specific wound 
healing over time following active and supportive periodontal therapy. Moreover, 
comparisons of microbiological and GCF inflammatory responses to periodontal 
therapy in smokers and non-smokers, contextualized with clinical treatment outcomes, 
may provide more in-depth understanding of the impact of smoking on active and 
supportive periodontal therapy. Summarizing, the research project on which this thesis 
is based was undertaken to analyse the impact of smoking on periodontal therapy, on 
the periodontal microflora, and on targeted inflammatory and bone remodeling 
markers in GCF at a patient, tooth, and site level.  
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3. AIMS  
The overall purpose of the present work was to evaluate the impact of smoking on the 
outcomes of periodontal therapy. 
Specific aims were as follows: 
 To study the site-specific effect of cigarette smoking on non-surgical and 
surgical periodontal therapy and to compare the composition of subgingival 
periopathogenic bacteria in smokers and non-smokers following non-surgical 
and surgical periodontal therapy (Study I). 
 To study the site-specific effect of cigarette smoking on supportive periodontal 
therapy and to compare predictive values of clinical parameters on the outcome 
of supportive periodontal therapy in smokers and non-smokers (Study II). 
 To determine the gingival crevicular fluid levels of inflammatory markers 
associated with periodontal inflammation and healing and the numbers of 
subgingival periopathogenic microflora following active and 12 months of 
supportive periodontal therapy in smokers and non-smokers.   
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4. MATERIAL AND METHODS 
4.1 Pre-study tests  
Intra-examiner (DFB) reproducibility was validated by registration of PD and CAL 
twice, one day apart, at six sites per tooth in a sample of 10 patients. Intra-class 
correlation coefficients (ICC) for the repeated measures for PD ranged between 0.92 
and 0.96 and for CAL between 0.93 and 0.96. The sample size was estimated based on 
change in PD with a difference of 0.5 mm considered clinically relevant. The standard 
deviation of the differences between repeated PD measurements from the intra-
calibration exercise was calculated to 0.5 mm. A power analysis based on 80 patients 
distributed into two groups and with the level of significance (α) set to 0.05, gave an 
88% power to detect a true difference of 0.5 mm.  
Prior to treatment, the hypothesis that it is not possible to mask an examiner to 
smoking status was tested in a pre-study sample of 30 chronic periodontitis patients, 
16 smokers (>10 cigarettes/day for at least 5 years) and 14 non-smokers (never or not 
in the last 5 years) enrolled in a supportive periodontal therapy program at the 
University Dental Clinic, Department of Clinical Dentistry - Periodontics, University 
of Bergen. Following removal of calculus, plaque, and staining and after a mouth rinse 
with 0.2% chlorhexidine gluconate (Corsodyl, GlaxoSmithKline, London, UK) for 1 
min, the examiner, wearing a face mask and masked to smoking status, scored 
smoking status as yes or no. Twenty-eight of 30 patients (93%) were correctly 
identified as either smoker or non-smoker. Thus, the pre-study hypothesis was 
accepted (p <0.001) indicating that the attempt to mask the examiner with regard to 
smoking status was unsuccessful. 
4.2 Ethics 
The study protocol and informed consent were approved by the Institutional Medical 
Research Ethics Committee, University of Bergen, Norway. Prior to inclusion in the 
study, participating patients read and signed the official informed consent form. 
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4.3 Study sample and study period 
Patients enrolled in the study were recruited from public and private dental clinics in 
three municipalities in Hordaland County, Norway, from December 2011 until June 
2014. Patients fulfilling study inclusion criteria were consecutively included from 
March 2012 through September 2013. The thesis is based on a prospective cohort 
study with data collected from April 2012 until March 2015.  
Study inclusion criteria accepted healthy subjects age 35-75 years diagnosed 
with chronic periodontitis and presenting with at least four non-adjacent teeth. These 
teeth should have proximal sites with a PD ≥6 mm and clinical attachment loss ≥5 mm 
with BoP and no radiographic signs of apical pathology. Subjects who presented with 
any current medical condition or used medications known to affect periodontal 
healing, or incorrectly reported smoking status, or had used antibiotics, or received 
subgingival scaling within 6 months of the study were excluded. The patients were 
either smokers (>10 cigarettes per day for at least 5 years) or non-smokers (never 
smoked or not within the last 5 years). Each patient, based on subjectively reported 
smoking status, was allocated into smoking or non-smoking group.  
Subjectively reported smoking consumption was calculated in packyears; the 
number of cigarettes smoked per day multiplied by the number of years divided by 20 
(the number of cigarettes in a standard package) (Scott et al. 2001). Smoking status 
was objectively validated prior to treatment by measuring cotinine levels in serum. 
Peripheral venous blood was taken from each patient before and following supportive 
periodontal therapy and the concentration of cotinine in serum determined using 







Figure 5. Study flow chart 
 
4.4 Clinical examination 
Before clinical examination, a full mouth series of intraoral radiographs was taken. 
Each patient underwent clinical examination of teeth and oral soft tissues performed 
by the same examiner (DFB). Clinical data were collected at baseline pre-treatment 
(T0), 3 months following active periodontal therapy (T1), and following 12 months of 
supportive periodontal therapy (T2). Rounding up to the nearest mm, PD was recorded 
as the distance from the gingival margin to the probeable base of the pocket and CAL 
as the distance from the cemento-enamel junction or the margin of a dental restoration 
to the probeable base of the pocket at six sites per tooth using a manual periodontal 
probe (PCPUNC 15, Hu-Friedy, Chicago, IL, USA). Full mouth gingival bleeding (BI) 
[213] and full mouth dental plaque (PI) was recorded [214] at the patient level and BoP 
and plaque scored as present/absent at the site-level.  
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3.5 Collection and analysis of biological samples  
Subgingival plaque, GCF, and serum were sampled from 80 patients at T0, 75 patients 
at T1, and 72 patients at T2. 
4.5.1 Subgingival plaque 
4.5.1.1 Collection procedure 
Subgingival plaque was collected using two sterile paper points. Plaque samples were 
immediately labelled and immersed into a pre-reduced sterile transport medium 
(PRAS Dental Transport Medium, Morgan Hill, CA, USA). The samples were taken 
from the same site as the GCF samples. 
4.5.1.2 DNA hybridization 
The subgingival plaque samples were analysed using DNA-DNA hybridization 
(checkerboard technique) [215] at Microbiological Diagnostic Service, Department of 
Oral Biology, Faculty of Dentistry, University of Oslo, Oslo, Norway. Each sample 
was qualitatively and quantitatively assessed for 20 periopathogenic bacteria. The 
analyses included red (P. gingivalis, T. denticola, and T. forsythia) and orange 
complex species (Prevotella intermedia, Prevotella nigrescens, Fusobacterium 
nucleatum subsp polymorphum, Fusobacterium nucleatum subsp nucleatum, 
Fusobacterium nucleatum subsp vincentii, Parvimonas micra), and A. 
actinomycetemcomitans. 
4.5.2 GCF  
4.5.2.1 Collection procedure 
GCF samples were collected using Periopaper strip (PERIOPAPER Gingival Fluid 
Collection Strips, Oraflow Inc., Smithtown, NY, USA). For each patient, one strip was 
inserted into the deepest periodontal pocket before treatment (T0) and resampled at the 
same site following active (T1) and supportive (T2) periodontal therapy. GCF volume 
was immediately estimated using the Periotron 8000 (Oraflow Inc., Smithtown, NY, 




4.5.2.2 Protein extraction and quantification 
GCF samples from 50 patients (25 smokers and 25 non-smokers) at T0, T1, and T2, 
were extracted using tris-HCl buffer and quantified using a commercially available kit 
(Pierce™ BCA Protein Assay Kit, Thermo Scientific, Rockford, IL, USA). A plate 
reader (FLUOstar OPTIMA- BMG Labtech, Ortenberg, Germany) measured the 
absorbance at 570 nm, total protein per sample measured in μg.  
3.5.2.3 Multi- and singleplex assays 
Bead-based singleplex essay was employed to detect two bone-remodeling markers 
(Human Bone Magnetic Bead Panel, Multiplex MAP Kit, Billerica, MA, USA): 
osteoprotegerin (OPG) and receptor activator for nuclear factor kappa-B ligand 
(RANKL). Bead-based multiplex essay was also employed to detect 27 inflammatory 
markers (Bio-Plex Human Cytokine Assay Bio-Rad Inc., Hercules, CA, USA): Basic 
Fibroblast Growth Factor (FGF), Eotaxin, Granulocyte Colony Stimulating Factor 
(G-CSF), Granulocyte-Monocyte Colony Stimulating Factor (GM-CSF), IL-1β, IL-2, 
IL-1ra, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12, IL-13, IL-15, IL-17, Interferon 
Inducible Protein-10 (IP-10), Interferon-γ (IFN-γ), Macrophage Inflammatory 
Protein-1α (MIP-1α), Macrophage Inflammatory Protein-1β (MIP-1β), Monocyte 
Chemo-attractive Protein-1 (MCP-1), Platelet-Derived Growth Factor (PDGF), 
Regulated Upon Activation, Normally T-Expressed and Presumably Secreted 
(RANTES), (TNF-α) and Vascular Endothelial Growth Factor (VEGF). 
3.6 Treatment 
Periodontal treatment was performed by one operator (DFB). Active periodontal 
therapy included non-surgical therapy, extraction of teeth with hopeless prognosis [216], 
and periodontal surgery. In patients with PI less than 25% and sites with persistent PD 
>5 mm with BoP about 2 months following non-surgical therapy, surgical therapy was 
pursued. Individualized surgical protocols comprised gingivectomy, open flap surgery, 
or open flap surgery in combination with regenerative therapy (Emdogain®). 
Supportive periodontal therapy was scheduled at 3-month intervals beginning 3 
months following active periodontal therapy. Smokers were regularly motivated to 
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reduce or stop smoking, and encouraged to participate in a public smoking cessation 
program (Røyketelefonen, Helsedirektoratet, Oslo, Norway).  
 
Figure 6. Study timeline. 
 
3.7 Statistical analysis 
The data were analyzed using the statistical software program Stata (Stata Corp., 
College Station, TX, USA), version 13 in Study I and II and version 14 in Study III. 
Distribution of continuous variables was tested in Study I with the skewness and 
kurtosis test and with the Shapiro-Wilk test in Study I and II. Numerical variables 
were expressed using means and standard deviations, means and standard errors of the 
mean, and means and range as appropriate. Differences between the continuous 
variables were assessed using a two-sample independent t-test and the Mann-Whitney 
test. Categorical variables were summarized as numbers and percentages and 
subsequently the chi-square test was used to identify differences. P-values <0.05 were 
considered statistically significant.  
Study I and II: Logistic regression analysis was performed to study the associations of 
different predictive variables with the outcome of active and supportive periodontal 
therapy in smokers and non-smokers. The site, corrected for clustering within patients, 
teeth, and sites over time, was the unit of the analysis and PD ≥5 mm with BoP was 
the outcome (dependent variable) dichotomized as present (1) or absent (0). Odds 
ratios (OR) with 95% confidence intervals (CI) were calculated. The OR expresses 
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differences in the risk to present the dependent variable between categories of 
independent variables. OR >1 imply an increased risk/chance, whereas OR <1 imply a 
decreased risk/chance. A non-significant outcome was understood if 1 was included in 
the 95 %. The sites presenting PD ≥5 mm with BoP at teeth extracted between T0 and 
T1 were not included in the analysis.  
Study I: Unadjusted analyses of relevant independent variables were performed. 
Variables with a p <0.05 in the unadjusted analysis plus gender, age, and baseline 
adjustments of four clinical parameters (PD, CAL, BI, and PI) were included in the 
unadjusted analysis to obtain adjusted ORs. Ordinary regression analysis, adjusted for 
clustering within patients over time, was undertaken to analyse the influence of active 
periodontal therapy on secondary outcome variables; clinical parameters and bacterial 
load.  
Study II: Presented as adjusted ORs, logistic regression model adjusted for age, 
gender, marital status, and education was applied to test the associations between the 
outcome (dependent variable) at T2 and predictive variables at T0 and T1. For the 
smoking effect model, the adjustments were supplemented for smoke with two dummy 
variables: (T2 = 1 and Smoke = 0) as (1) and (T2 = 1 and Smoke = 1) as (0) and (T1 = 
1 and Smoke = 0) as (1) and T1 = 1 and Smoke = 1) as (0). The model was constructed 
to study the effect of smoking at the differences between outcomes following active 
and supportive periodontal therapy. Multilevel analysis was used to calculate ICC 
within patients, teeth, and sites using linear mixed effects models. The multilevel 
model was set up as a random intercept model using melogit. 
Study III: Based on a subsample of 25 heavy smokers and 25 non-smokers a post-hoc 
power analysis was performed. A level of significance (α) set to 0.05, gave a 71% 
power to detect a true difference of 0.5 mm. Due to skewed distribution of the data, 
square root transformation was employed. Ordinary regression analysis adjusted for 
clustering of time and for multiple comparisons (Sidak post-hoc test) was undertaken 
to analyse the influence of active and supportive periodontal therapy on the amounts 
and concentrations of markers in GCF. Red complex bacteria were categorized as > or 
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<105 number of species and plaque as present or absent. Stratified by plaque and red 
complex species, a regression model adjusted for age, gender, education, and 
clustering over time was applied to test the associations between smoking and amounts 
of markers. By calculation of the effect size, the impact of smoking on the amounts of 
markers before therapy and following active and supportive periodontal therapy was 
reported as Cohen`s coefficient. Cohen`s coefficient expresses the magnitude of 





This section provides a brief summary of the results presented in the three reports 
(Study I, II, and III) that constitute the thesis. 
5.1 Study I 
The specific aim was to compare site-specific treatment outcomes in smokers and non-
smokers following non-surgical and surgical periodontal therapy. Seventy-five of the 
80 included patients, 40 smokers and 40 non-smokers, were available for examination 
following active periodontal therapy. Drop-outs included two smokers and three non-
smokers. Mean age for smokers was 58 years (range 37-70) and for non-smokers 59 
years (range 35-73); the percentage male smokers and non-smokers estimated to 38% 
and 58%, respectively. At baseline, mean reported smoking was 37 packyears (range 
20-108) and mean cotinine level 471 ng/mL (range 168-861). None of the patients 
were excluded because of incorrect reporting of smoking status following cotinine 
validation and no patients reported starting or stopped smoking during Study 1.  
Patient level clinical and microbiological outcomes following active periodontal 
therapy  
More teeth were extracted in smokers compared with non-smokers (37 vs 11) 
following active periodontal therapy.  Both smokers and non-smokers demonstrated 
significant reductions in mean PD, CAL, BI, and PI (p <0.001). Total sites presenting 
PD ≥5 mm with BoP were 26.4% (n = 1471) for smokers and 17.5% (n = 1049) for 
non-smokers. Within arch and tooth type, the numbers of PD ≥5 mm with BoP were 
significantly higher at maxillary single rooted teeth in smokers compared with non-
smokers (p = 0.030). Both smokers and non-smokers responded to active periodontal 
therapy with a reduction of PD ≥5 mm with BoP to 132 (3%) and 52 (1%) sites, 
respectively. Following active periodontal therapy, five smokers (mean cotinine 727 
ng/mL) presented more than 10 persistent sites with PD ≥5 mm with BoP, whereas no 
non-smokers presented more than seven sites. A significant reduction of red complex 
species was observed in non-smokers (p = 0.010). For single species within the red 
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complex, T. forsythia was significantly reduced in smokers (p = 0.038) and 
T. forsythia and P. gingivalis in non-smokers (p = 0.005 and p = 0.013, respectively). 
Site level clinical outcomes following active periodontal therapy 
 PD ≥5 mm with BoP was more likely to occur in smokers than in non-smokers 
(unadjusted OR = 2.01, p = 0.004, adjusted OR = 1.90, p = 0.013) following active 
periodontal therapy. Compared with a plaque free site in non-smokers, presence of 
plaque increased the risk for PD ≥5 mm with BoP in smokers and non-smokers (OR = 
4.14, p <0.001 and OR = 3.09, p <0.001, respectively). The risk was significantly 
greater in smokers within every tested location, except for maxillary buccal sites. 
Compared with plaque free sites in non-smokers, smokers were more likely to present 
with PD ≥5 mm with BoP at maxillary teeth (OR = 1.25, p = 0.029) and at buccal sites 
in maxillary multi-rooted teeth (OR = 1.31, p = 0.045).  
5.2 Study II 
The specific aim was to compare site-specific treatment outcomes in smokers and non-
smokers following supportive periodontal therapy. Seventy-two (36 smokers and 36 
non-smokers) of the 80 included patients (40 smokers and 40 non-smokers) were 
available for examination following supportive periodontal therapy. In addition to the 
five patients lost during active periodontal therapy, two smokers and one non-smoker 
dropped out during supportive periodontal therapy. Assessments of socio-demographic 
status of the drop-out patients did not differ significantly from patients completing the 
study. Three smokers reported stopping smoking during supportive periodontal 
therapy, two of whom were confirmed by cotinine levels <10 ng/mL.  
Patient level clinical outcomes following supportive periodontal therapy  
Mean PD, BI, and PI increased significantly in smokers and non-smokers and the 
number of sites presenting with PD ≥5 mm with BoP increased from 132 (3%) to 180 
(3.8%) in smokers and from 52 (1%) to 79 (1.6%) in non-smokers. The greatest 
increase was observed in smokers at maxillary single-rooted teeth with an increase 
from 25 (2.6%) to 48 (5.4%) sites. At baseline, prior to active and supportive 
periodontal therapy, 39 smokers and 39 non-smokers presented nine or more sites with 
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PD ≥5 mm with BoP. These smokers reported a smoking of 36.9 packyears (95% CI 
36.4-37.4) and exhibiting a mean cotinine level of 474 ng/mL (95% CI 470-479). 
Following supportive periodontal therapy, five smokers and one non-smoker presented 
nine or more sites with PD ≥5 mm with BoP and among the smokers, smoking 
estimated to 35.5 packyears (95% CI 35.0-36.0) with a cotinine level of 697 ng/mL 
(95% CI 682-719). 
Site level clinical outcomes following supportive periodontal therapy 
Mean PD at baseline and following active periodontal therapy was slightly more 
predictive for PD ≥5 mm with BoP in non-smokers than in smokers following 
supportive periodontal therapy. BoP was a significant predictor in both smokers and 
non-smokers. Following active periodontal therapy BoP was a stronger predictive 
factor in smokers than in non-smokers (OR = 13.26, p <0.001 and OR = 4.68, p 
<0.001, respectively). Plaque following active periodontal therapy was a more 
significant predictor in smokers (OR = 5.83, p <0.001) than in non-smokers (OR = 
2.29, p = 0.041). Smoking had an overall negative effect on the outcomes of 
supportive periodontal therapy (OR = 2.78, p = 0.001), and the effect were more 
pronounced at maxillary single rooted teeth (OR = 5.08, p = 0.001). The random 
intercept models used to account for patient, tooth, and site over time, showed 
variations at site, tooth, and patient levels (ICC = 0.76, ICC = 0.59, and ICC = 0.11, 
respectively]. The variance at patient level was less in smokers than in non-smokers 
(ICC = 0.137 and ICC = 0.051, respectively).   
5.3 Study III 
The specific aim was to investigate the effect of smoking on the inflammatory 
response following active and supportive periodontal therapy as estimated in GCF. 
Moreover, the number of subgingival periopathogenic bacteria was estimated. A 
subsample of 25 heavy smokers and 25 non-smokers from the original 80 patients was 
selected based on baseline cotinine levels. Inclusion criteria for smokers and non-
smokers were cotinine levels in serum ≥300 ng/mL for smokers and <10 ng/mL for 
non-smokers. The following bone and inflammatory markers were reported: OPG, G-
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CSF, GM-CSF, IL-1β, IL-1ra, IL-4, IL-6, IL-7, IL-8, IL-9, IL-10, IL-17, IP-10, IFN-γ, 
MIP-1α, MIP-1β, PDGF, RANTES, TNF-α, and, VEGF. 
Measured by a negative effect size, smoking induced an overall reduced 
expression of bone and inflammatory markers in GCF at baseline and following 
supportive periodontal therapy (both, p <0.001). Subgroups of markers based on 
functionality, showed that smoking suppressed pro-inflammatory markers (p <0.001), 
chemokines (p = 0.007), and growth-factors (p = 0.003) at baseline, bone-remodeling 
markers (p = 0.003) following active periodontal therapy, and pro-inflammatory 
markers (p = 0.019) and chemokines (p = 0.005) following supportive periodontal 
therapy. Only one specific marker, chemokine IL-8, was detected in significantly 
higher amounts in smokers compared with non-smokers following supportive 
periodontal therapy (p = 0.034). Ten of the investigated markers in non-smokers were 
significantly upregulated following periodontal therapy whereas none in smokers. 
More specifically, for non-smokers a downregulation was observed for IL-1β, TNF-α, 
IL-7, GM-CSF, IFN-γ, IL-10, VEGF and IP-10 following active periodontal therapy 
and an upregulation for TNF-α, IL-7, IL-9, IFN-γ, IL-10, PDGF, and IP-10 following 
supportive periodontal therapy.  
 In the adjusted analysis, smoking was negatively associated with the amounts of 
pro-inflammatory (p = 0.042), anti-inflammatory markers (p = 0.012), and OPG (p = 
0.001) at sites presenting more than105 red complex bacteria. Moreover, the amounts 
of markers for every investigated group (pro- and anti-inflammatory, chemokines, 
growth-factors and bone-remodeling markers) showed a significant negative 
association with smoking at plaque positive sites and a positive association at plaque 




6. GENERAL DISCUSSION 
6.1 Methods 
6.1.1. Study design and patients 
Current smoking is considered an important modifiable risk factor for all severities of 
periodontitis [19]. The series of studies included in this thesis addresses the impact of 
smoking on periodontal therapy, on the subgingival microflora, and on inflammatory 
and bone remodeling GCF markers in chronic periodontitis patients. Generally, 
randomized controlled trials are considered the highest standard in clinical research 
providing the strongest level of evidence controlling for bias and confounding factors. 
However, a randomized controlled trial study design is not always possible or 
necessary particularly studying the effect of smoking exposure on periodontal 
treatment outcome. The present study can be defined as a prospective cohort study 
with one exposed and one non-exposed population. A prospective design may reduce 
selection bias by direct assessment of smoking exposure, controlling strict exclusion 
and inclusion criteria, and reducing recall bias by defining regular recall interval and 
time for data collection. On the other hand, lack of masking might introduce 
performance bias. However, masking the operator or examiner is not always possible 
and false masking could also introduce bias. The pre-study test demonstrated that a 
dentist cannot be masked relative to smoking status in current smokers. Thus, the 
critical issue of masking examiners or operators to smoking status is challenging and 
may introduce bias. 
All patients in the present study were referred for periodontal therapy from 
general practitioners and represented adult motivated patients who previously had 
attended recall programs. The consecutively enrolled patients within the smoking and 
non-smoking cohort were not matched relative to sociodemographic or clinical 
characteristics. A higher female/male ratio in smokers compared with non-smokers 
occurred as more male than female smokers were excluded due to systemic health 
conditions affecting periodontal therapy. This could represent a confounder as females 
tend to exercise better compliance and oral hygiene regimens [217, 218] and exhibit a 
reduced pro-inflammatory response than males [219]. Marital status and education levels 
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were also unbalanced with smokers presenting lower education levels and living alone 
[220, 221]. Low education level is negatively associated with periodontal progression 
independent of smoking status [222, 223] and should be considered a confounder for 
impaired treatment outcomes in smokers. 
The two cohorts were not balanced for disease severity and the study sample 
reflected an average severity of chronic periodontitis among adult smokers and non-
smokers. Chronic periodontitis in smokers is generally manifested by deeper PDs and 
lesser BoP than in non-smokers [19]. Diagnosis and threshold levels for case definition 
did not secure an equal distribution of moderate and severe chronic periodontitis 
within the smoking and non-smoking cohort. As most smokers were exposed to 
smoking for decades prior to therapy, modulated inflammatory responses and 
aggravated periodontal pathogens have probably induced a more severe periodontal 
attachment loss, deeper PDs, and suppressed BoP compared with non-smokers [152]. 
Thus, severe periodontal disease in smokers may show less reduction of diseased sites 












Figure 7. Mean PD (a) and BoP (b) in smokers and non-smokers at T0, T1, and T2. 
In younger populations differences in clinical characteristics between smokers 
and non-smokers might have been more pronounced [225]. Since the two principle 
forms of periodontitis, chronic and aggressive, may not be discriminated in the setting 
of one clinical examination, the age group makes it more likely that enrolled patients 
represented true chronic periodontitis [226].  Treatment of severe chronic periodontitis is 
demanding as deeper PD and furcations generally predispose for more remaining 
plaque and calculus following non-surgical therapy [227]. Therefore, deeper PD and 
CAL presented in smokers at baseline could introduce a selection bias in the study 
sample by reduced treatment outcomes related to differences in subgingival plaque 
rather than smoking status. In total, periodontal surgery was performed in 35 smokers 
and 30 non-smokers and the greatest number of sites included in each surgery was in 
smokers. The surgical approach used depended on disease severity. As smokers 
presented with more advanced periodontal disease at baseline, more operator-sensitive 
surgical techniques were used. However, follow-up studies of periodontal therapy 
show that plaque control and adherence to a maintenance program may have a greater 
impact on treatment outcomes than the actual surgical intervention [40, 41, 228]. In 
perspective, smokers have demonstrated reduced compliance to supportive periodontal 
therapy [114]. A strict follow-up interval every 3 months was the setup during 




Sampling sites for GCF in smokers and non-smokers presented with no 
significant differences in PD, CAL, BI, PI, and GCF volume. However, regardless of 
smoking, the expression of markers in GCF is influenced by patient related factors 
including mean PD and CAL [229]. Therefore, local expression of GCF following 
periodontal therapy could be considered comparison of responses to subgingival 
plaque removal within specific host traits in smokers and non-smokers [32, 230]. 
A multicentre study design would have made it possible to increase the sample 
size. On the other hand, using one operator excluded inter-individual variability. 
Repeated measurements of PD performed by the examiner (DFB) were used to 
calculate the standard deviation and the sample size estimation by including 80 
patients gave an 88% power to detect a true difference of 0.5 mm. In Study III, the 
sample size was reduced due to drop-outs, smoking cessation, and the objective of 
investigating effects of heavy smoking defined by cotinine levels in serum. Post-hoc 
power analysis was calculated to 71%.  The eight (10%) drop-outs were balanced 
within the smoking (10%) and non-smoking (10%) cohorts and did not significantly 
vary by sociodemographic characteristics. Five (three smokers) of the excluded 
patients were removed from the study due to non-periodontal infections treated with 
systemic antibiotics.  Systemic antibiotic could be considered an integrated part of 
performed periodontal treatment. However, antibiotic therapy was not an intervention 
and antibiotic used for systemic conditions could not be standardized nor controlled. 
Therefore, patients using systemic antibiotic were excluded throughout the study. One 
smoker not following the rigid supportive periodontal therapy interval was also 
excluded.   
6.1.2 Choice of outcome variable 
Two levels of chronic periodontitis definitions were employed in Study I and II. At the 
patient level a periodontitis case was defined and diagnosed by periodontal parameters 
according to two consensuses for case definitions (AAP /EFP). At the site level a 
periodontal disease site was defined by PD ≥5 mm with BoP. At present, there is no 
generally accepted definition of a periodontal disease site and studies have generally 
reported mean number of sites with PD ≤4 mm and PD ≥4 mm, presenting periodontal 
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health and periodontal disease, respectively [231]. However, as a rule past experience of 
periodontitis is measured by attachment- and bone loss and present disease by BoP 
and/or PD [11]. Few studies have been conducted using site as unit of analysis. One 
multilevel study reporting 3-month outcomes following non-surgical periodontal 
therapy in non-smokers and smokers defined a periodontal healthy site as PD <4 mm 
without BoP [175]. In contrast, the present study defined a periodontal disease site as PD 
≥5 mm with BoP. One may argue that including BoP in the primary outcome variable 
might introduce a bias as smokers tend to show suppressed BoP and gingival bleeding 
compared with non-smokers [167, 232]. However, BoP in both smokers and non-smokers 
seems to indicate periodontal instability. A 5-year follow-up study reported increased 
mean BoP associated with periodontal instability and disease severity in smokers and 
non-smokers [107]. Another study applying site-specific data adjusted for clustering 
within patients and sites, reported 86% increased risk for transition of a non-bleeding 
to a bleeding site in smokers compared with non-smokers [233]. In contrast, excluding 
BoP as the primary outcome variable might introduce another bias by favouring PD 
reduction in non-smokers due to increased tissue probing penetration at baseline [234] 
and greater gingival shrinkage following resolution of inflammation [171]. As a site-
level periodontal diagnosis including BoP appears associated with disease progression 
and periodontal instability irrespective of smoking status, both PD and BoP were 
included in the primary outcome variable. 
6.1.3 Choice of biological sampling techniques and analysis 
6.1.3.1 Plaque 
The outcome of microbiological diagnostics may to some degree depend on the 
method of subgingival plaque sampling. Paper points and curette sampling are widely 
used. Compared with curettes, paper points may collect unattached bacteria and 
bacteria from the outer layer of plaque [235]. Conversely, in deep pockets, paper points 
are criticized to be saturated with moistness and plaque already in the shallower layer 
of the pockets [236]. Moreover, higher bacterial DNA counts have been detected from 
curette samples compared with paper points [26]. Nevertheless, the two sampling 
techniques have resulted in similar microbiological findings [237, 238]. In Study I and III 
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subgingival plaque samples were collected using sterile paper points (ISO size 40). As 
paper points absorb GCF, GCF sampling was performed in advance of subgingival 
plaque sampling [239]. GCF sampling prior to plaque sampling does not seem to 
interfere with detection of subgingival microbiota at periodontitis sites [240].  
The plaque samples were analysed by using the semi-quantitative checkerboard 
DNA-DNA hybridization technique. The technique was developed for detection and 
quantification of periopathogenic bacteria and is useful in exploring presence of red 
complex species. Other techniques with a higher specificity and sensitivity could 
analyse the complete oral microbiome and reduce false negatives, especially following 
periodontal therapy [241]. Nevertheless, the DNA-DNA hybridization technique 
identifies associations between periopathogenic bacteria and periodontal health and 
has been shown to distinguish samples from different PD categories similarly as PCR, 
a high true put technique [242].  Furthermore, contextualized within the framework of 
the keystone pathogen hypothesis [27], limitations regarding quantification and 
specificity may not be of clinical relevance. 
6.1.3.2 Gingival crevicular fluid  
GCF provides a protective role in host-parasite interactions by physically diluting 
bacteria and their metabolites and presenting antibacterial substances into the pocket.  
Inflammatory markers in GCF may be indicators of periodontal disease as well as 
periodontal wound healing. GCF can be collected by absorbent strips, capillary tubes, 
or gingival washing [243]. In Study III pre-sterilized periopaper filter strips were 
considered the preferred method compared with gingival washing [243, 244]. Detailed and 
calibrated collection methods that enable replication are recommended; standardized 
collection of GCF in broad terms performed using two approaches [244]. The first 
approach measures GCF volume and the second standardizes the collection time. The 
volume can be directly estimated using a Periotron reader that enables calculations of 
target cytokine markers at pg/μl-levels based on the sampled GCF volume. Weighing 
strips before and after sampling is not recommended due to minor changes in strip 
weight requiring very sensitive scales [245]. The alternative method is more prevalent 
and reports the total amount GCF collected in a standard period of time, frequently per 
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30 seconds. In Study III, collection time was standardized and the results reported as 
total amount per 30 seconds. Reduced periodontal inflammation following periodontal 
therapy resulted in decreased GCF volume for both smokers and non-smokers and 
decreased volume could have an excessive effect on concentration of markers and 
potentially elevate their concentrations in GCF. Therefore, reporting total amount per 
30 seconds appears preferred compared with corrections for original GCF volume in 
prospective studies [244]. 
 Within the complex nature of chronic periodontitis, a single marker cannot 
reflect the overall inflammatory response to periodontal therapy and although ELISA 
is considered a preferred standard in the analysis of inflammatory markers, the 
multiplex technique offers the advantage of detecting up to 100 different markers in a 
relatively small sample. Moreover, multiplex is a high throughput technique offering 
similar sensitivity as ELISA [246]. Captured antibodies and antigens are freely 
suspended inside reaction wells in multiplex plates compared with antibodies attached 
at the bottom of the wells in ELISA plates [246]. Therefore, the multiplex technique 
used in Study III may provide an overall picture of the local inflammatory response to 
periodontal therapy in smokers and non-smokers.  
6.1.4 Statistical analysis 
The longitudinal study design was initiated to compare the changes in clinical 
parameters, subgingival plaque, and GCF markers following periodontal therapy in 
smokers and non-smokers. In Study I and II disease sites were the unit of the analysis. 
Reporting mean values of full-mouth measurements have tended to fail in 
investigating disease progression due to dilution by a major number of non-diseased 
sites [247]. Logistic regression analysis was a natural choice for statistical analysis with 
the binary outcome variable PD ≥5 mm with BoP (present vs not present). Previous 
studies analysing periodontal therapy have mostly used single level statistical models 
assuming that site-level observations are independent. Patients are generally 
considered independent units and commonly site-specific measurements have been 
averaged to subject means. To take into account the dependency receding by the 
natural hierarchical structure of site-specific data within patients and teeth and by the 
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repeated measures in the prospective study design, all analysis was adjusted for 
dependencies.  
                          
Figure 8. The hierarchical clustering of periodontal data, at T0, T1, and T2 and at six 
sites in maximum 28 teeth, in Study I and II. 
 The use of random effect models (logistic multilevel analysis) was in Study II 
an appropriate way to model and report the clustered data. Repeated measures for three 
time points were clustered within sites, teeth, and patients. At every level of 
hierarchical clustering of data the ICC indicates the proportion between cluster 
variances and total variance. The total variance regarding number of disease sites was 
related to within- and between-level differences. A high ICC implied hence that 
between group variance dominated over within group variance. In contrast, a small 
ICC indicated that more of the variance was related to differences within the groups, 
since the between observations within the group is smaller [248]. 
In study III all analysis was performed at patient level and adjustments were 
done for clustering of repeated measures. By calculations of both p-values and effect 
sizes, the hypothesis could test if smoking affected expression of GCF markers 
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following therapy and moreover, how smoking affected the expression of GCF 
markers and the magnitude of the effect [249].    
6.2 Results 
6.2.1 Smoking and surgical and non-surgical periodontal therapy 
Non-surgical and surgical periodontal therapy efficiently reduced mean patient related 
variables as BI, PI, PD, and CAL and the number of diseased sites in smokers as well 
as in non-smokers. However, smokers were more likely than non-smokers to exhibit 
diseased sites (PD ≥5 mm with BoP) following therapy (OR 2.01). The results are in 
accordance with previous findings documenting that non-surgical and surgical 
periodontal therapy has a therapeutic, but lower effect in smokers [163, 164, 193].  
Responses to periodontal therapy are commonly compared with baseline recordings. 
As smokers tend to have deeper PD and CAL than non-smokers and when a baseline 
measure is part of the treatment outcome, the efficacy of therapy might be 
algebraically coupled to baseline measures [250]. Correction of differences in baseline 
variables in the adjusted analysis supported a suppression of site-specific treatment 
outcome following active periodontal therapy in smokers (OR 1.90). However, the risk 
of persisting diseased sites was more strongly associated with baseline PD in non-
smokers, indicating that the outcome of active periodontal therapy is less dependent on 
initial PD.  
Though the principle of active periodontal therapy is non-specific removal of 
plaque and calculus by various debridement techniques, PI was not a significant 
outcome factor in either smokers or non-smokers. Other studies as well have failed to 
demonstrate an association of PI and treatment outcomes [175, 251]. Few studies have 
considered plaque at a site-level as a determining outcome factor of periodontal 
therapy. In the present study, a plaque positive site increased the risk for persisting 
disease. This finding is in line with previous longitudinal studies reporting plaque at 
site-level as a critical outcome factor [173, 175]. Specifically, plaque positive lingual sites 
at multi-rooted mandibular teeth demonstrated the highest risk for persistent disease 
sites in smokers and non-smokers. Obtaining adequate plaque control at these sites 
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appears challenging [252]. Therefore, self-performed daily oral hygiene routines 
providing plaque free sites in those areas should be emphasized. Previous reports have 
shown reduced probability of pocket closure (PD ≤4 mm without BoP) at plaque 
positive sites in smokers [175]. This finding is supported by the present study which 
indicated a four times higher risk of persistent disease at plaque positive sites. 
Smoking appears to reduce the site-specific tolerance to plaque thus effective self-
performed oral hygiene routines in smokers appear critical. Site-specific variations 
were detected as plaque positive palatal sites at maxillary multi-rooted teeth in 
smokers presented a higher risk of disease sites while the palatal sites at single-rooted 
teeth in maxilla presented a lower risk. The explanation could be that smokers have 
more furcation involvements than non-smokers, especially in maxillary multi-rooted 
teeth [253, 254] with demanding access for instrumentation. Moreover, maxillary molar 
palatal sites appear particularly exposed to tar from tobacco smoke. Failure to 
discriminate attached tar from plaque may have led to misinterpretation of plaque 
positive sites in smokers.  
6.2.2 Smoking and supportive periodontal therapy 
During supportive periodontal therapy a slight relapse of periodontal disease occurred 
as shown by increased patient level mean BI, PI, and PD and number of diseased sites 
in smokers and non-smokers. While active periodontal therapy reduced the number of 
diseased sites in all locations, the number of diseased sites increased followed 
supportive periodontal therapy. A higher risk for relapse was detected in smokers in all 
areas, demonstrating that the strict recall care every 3 months was not sufficient to 
outweigh the negative effect of cigarette smoking. Longitudinal studies have 
previously reported both reduced and similar responses in smokers compared with 
non-smokers over years with regular follow-up regimes [201, 255, 256]. However, as these 
studies compared changes in mean patient levels of both healthy and diseased sites, a 
direct comparison with the present study using site as the unit of the analysis is 
inappropriate.    
Site-level differences are known to contribute most to the variance in outcomes 
following non-surgical periodontal therapy [173, 175, 251]. This also applies to the present 
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study. Moreover, stratified by smoking, ICC showed higher variation at patient level in 
non-smokers supporting smoking being a major patient related risk factor. 
Following supportive periodontal therapy, the number of diseased sites at 
maxillary single-rooted teeth increased by 80.5 % in smokers (from 41% to 84%). 
Generally, in smokers, maxillary teeth present with the most advanced attachment loss 
and the deepest periodontal pockets [257], also shown in the present study. Furthermore, 
the adjusted analysis revealed a stronger effect of cigarette smoke at maxillary single 
rooted teeth with less variation at patient level. A local effect of smoking on 
periodontal tissues has rarely been considered in previous studies, but an additive 
effect from direct exposure of smoking on the systemic effect has been suggested [258]. 
Maxillary single-rooted teeth are more directly exposed to smoking and may be more 
susceptible to impaired periodontal healing. The early phase of wound healing 
following active periodontal therapy might be less influenced by a direct exposure to 
cigarette smoke compared with the subsequent tissue remodeling during supportive 
periodontal therapy.  
In the present study, BoP at site-level appeared to be a risk factor for disease 
progression and especially in smokers during supportive periodontal therapy. BoP 
from deep periodontal pockets has previously been associated with more prevalent and 
more intense BoP following non-surgical therapy [259]. Therefore, BoP at PD ≥5 mm 
may be considered a predictive risk factor for inferior treatment outcome during 
supportive periodontal therapy in smokers. Generally, smokers appear with suppressed 
gingival bleeding and BoP [232], most likely due to a different distribution of small and 
large capillaries in gingival tissues and vasoconstrictive adaption to periodontal 
disease [260]. The biological mechanisms, however, for suppressed gingival bleeding in 
smokers remain unclear.  
6.2.3 Smoking exposure and response to periodontal therapy 
Smoking appears a major modifiable risk factor in periodontal diseases also affecting 
periodontal therapy, but unfortunately is not that easy to modify for patients and 
clinicians. Smoking cessation is a predictive factor for positive treatment responses 
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and already within days following smoking cessation periodontal parameters are 
positively affected [59, 261]. None of the patients reported to stop smoking during active 
periodontal therapy, but three out of 35 stopped smoking during supportive periodontal 
therapy. The reduced prevalence and the growing social disapproval of smoking, 
advocate more hardcore smokers, meaning smokers who have smoked for many years 
with no intention to stop [262]. Such hardening of smokers has been confirmed in 
Norway [263], whereas in Netherlands the “hardening hypothesis” has been rejected, 
especially among highly educated persons [264]. Nevertheless, regulation and decline in 
smoking prevalence in Scandinavia have been successful, leading the way for smoking 
regulation in other countries [151]. A coincidental increased use of snuff in Scandinavia 
might partly explain the reduction in number of smokers [265]. There is an ongoing 
debate whether snuff actually prevents adolescents from starting smoking [266] and the 
magnitude of health profit by substituting smoke with non-combustible tobacco 
products [267]. A well-known tobacco researcher claimed that “People smoke for the 
nicotine but they die from the tar” [268]. By reducing or eliminating the content of 
nicotine from combustible tobacco products, the dependency and thereby the use of 
the products may decline. Therefore, in contrast to e-cigarettes and snuff, cigarettes 
with reduced nicotine might be a promising path to smoking cessation [269].  
Previous studies have demonstrated a dose-dependent detrimental effect of 
smoking on periodontal healing in which smoking exposure is subjectively reported in 
packyears or number of smoked cigarettes per day [86, 201]. However, lack of 
standardization of smoking status may to some extent explain an inconsistent dose-
dependent effect of smoking on periodontal therapy [193]. A precise and objective 
measure of smoking exposure is essential to address the effect of smoking on 
periodontal healing.  High cotinine levels in serum following supportive periodontal 
therapy were associated with nine or more remaining diseased sites within patients. 
Heavy smoking during therapy appeared to suppress the overall treatment responses 
resulting in more diseased sites, supporting a dose-response to periodontal therapy. A 
similar trend was not observed between subjectively reported number of cigarettes and 
treatment outcomes. Cotinine, a nicotine metabolite, is stable for up to 19 hours and 
considered an accurate measure of present smoking exposure [270].  In comparison, 
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packyear appears a less precise estimation of smoking exposure over several years. 
Underreporting smoking could mask an association between treatment outcome and 
exposure. Another confounding factor might be underreported use of other nicotine 
delivery products as moist snuff and electronic cigarettes [271], especially during 
smoking cessation. An effect of snuff and electronical cigarettes on chronic 
periodontitis has not been documented [272, 273].  
6.2.4 Periopathogenic bacteria and local inflammatory response to periodontal 
therapy 
Reduced numbers of anaerobic bacteria generally occur following periodontal therapy 
[274]. No significant reduction in the numbers of red and orange complex species was 
observed in smokers following active periodontal therapy, whereas a significant 
reduction in red complex species was observed in non-smokers. Smoking is considered 
to have a profound impact on the morphology, physiology, and formation of dental 
plaque [275] and on the distribution of periodontal pathogens [177]. Increased numbers of 
bacteria from the red and orange complex have been detected in smokers with chronic 
periodontitis before treatment and following periodontal therapy [62, 178]. Smoking may 
through changes in temperature, pH, nicotine, and release of chemicals disturb the 
periodontal ecology by modulating local and systemic host immune responses [275]. 
Furthermore, bacterial physiognomies may adapt to smoke. Especially the keystone 
pathogen P. gingivalis responds with enhanced ability to colonize and invade epithelial 
cells [276]. As smoking stimulates plaque formation in a dose dependent way and is 
reversed by removal of smoking exposure [277, 278], a local detrimental effect of 
smoking on periodontal disease and treatment outcome is endorsed. Nevertheless, 
P.gingivalis is not considered a primary inducer of inflammation causing periodontal 
attachment loss, but a manipulator of a dysbiotic periodontal microbiota giving rise to 
destructive host responses [28]. Smoking may exert a selective influence on dysbiotic 
development in the subgingival plaque persuading upgrowth of commensals or new 
subgingival bacteria, termed pathobionts, which may partly explain poor responses to 
periodontal therapy in smokers.  
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The periopathogenic species in subgingival plaque interact with release of 
biomarkers in GCF [279] and following active periodontal therapy in non-smokers, 
inflammatory markers in GCF were reduced. Compared with non-smokers, smokers 
demonstrated suppressed amounts of cytokines in GCF at baseline and following 
supportive periodontal therapy. Active periodontal therapy reduced the amount of 
inflammatory markers in non-smokers and thereby decreased differences in expression 
of markers between smokers and non-smokers. Variations in biomarkers in GCF 
generally mirror fluctuations of quiet periods and bursts of activity in chronic 
periodontitis [8]. However, smoking appears to outweigh expression related to activity 
by a downregulation of cytokines and, furthermore, by an overall suppression of pro-
and anti-inflammatory markers at sites positive for plaque and for higher counts of 
red-complex species. A hypoexpression of cytokines in smokers with chronic 
periodontitis has previously been recognised [280-282]. In contrast, smoking has also 
been associated with increased pro-inflammatory responses to bacterial colonization 
[283] and not to be a major modifier of inflammatory markers in GCF in severe chronic 
periodontitis [32].  
Only one investigated molecule, IL-8, was detected in significantly higher 
amounts in smokers following supportive periodontal therapy. This chemokine has 
been recognized as a marker with major pro-inflammatory properties attracting 
neutrophils and being upregulated by smoking in a dose-responding manner [284].  
Levels of cotinine are known to vary considerably in different body fluids [285]. GCF 
may have 300-fold higher levels of nicotine than serum [286]. Therefore, local 
expression of IL-8 could be expected to vary from site to site in heavy smokers. 
Higher levels of IL-8 seem to increase survival of gingival fibroblasts [287] and alter 
chronic wound healing by inducing fibrosis of gingival tissues.  Interestingly, 
increased IL-8 might impair periodontal healing, especially at maxillary single-rooted 
teeth where a local effect of heavy smoking appears more evident. 
Bone formation and resorption is a dynamic process controlled by the bone-
remodeling markers RANKL and OPG [288]. The remodeling process is regulated by 
the RANKL:OPG ratio as OPG binds to the cellular receptor of RANKL, blocking 
RANKL from activating osteoclasts. Increased GCF ratio has been detected in chronic 
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periodontitis patients [289] and is either caused by decreased OPG, increased RANKL, 
or both. Aggravated alveolar bone loss is a diagnostic feature of chronic periodontitis 
in smokers [160]. The concentration of RANKL was below detection level in the present 
study. However, OPG was significantly reduced in smokers compared with non-
smokers following active periodontal therapy, indicating an increased RANKL:OPG 
ratio. Decreased OPG production has previously been revealed in osteoblasts 
following nicotine exposure in a dose dependent manner [290]. Using a threshold of 
smoking more than 20 packyears of cigarettes, a decrease in OPG and a higher 
RANKL:OPG ratio has been reported [291]. Findings in the present study support these 
findings and indicate that heavy smoking may increase tissue degradation by 





Independently of disease severity and smoking status, overall non-surgical and 
surgical periodontal therapy resulted in favourable treatment outcomes. However, 
smokers exhibited an impaired site-specific response to active periodontal therapy 
documented by an increased risk to present with diseased sites in a dose-dependent 
manner. Only non-smokers demonstrated reduced numbers of red-complex microbiota. 
Plaque positive sites were at higher risk of limited treatment outcomes in smokers and 
reduced tolerance for plaque at site-level in smokers might be linked to aggravated 
subgingival dental plaque.  
 Following 12 months of supportive periodontal therapy, a higher incidence of 
diseased sites was detected in smokers than in non-smokers. A negative site-specific 
effect of smoking was observed, especially at maxillary single-rooted teeth. Elevated 
levels of cotinine were more related to numbers of disease sites than smoking 
estimated by packyears, indicating the relevance of reducing or terminating smoking 
during periodontal therapy. Following active periodontal therapy bleeding on probing 
was a strong predictor for disease site, especially in smokers. 
 No inflammatory and bone remodeling markers in gingival crevicular fluid 
responded to active and supportive periodontal therapy in smokers. In contrast, the 
local expression of inflammatory and bone remodeling markers in non-smokers was 
altered by active periodontal therapy. Only in non-smokers did inflammatory markers 
reflect the recurrence of chronic periodontitis during supportive periodontal therapy.  
 Within the limitations of the present study, it may be concluded that dampened 
local inflammation, especially at plaque positive sites and at sites harbouring high 
levels of red complex species, contribute to the impaired site-specific treatment 




8. FUTURE PERSPECTIVES 
Globally, the number of smokers continues to increase. An obvious way to improve 
the outcome of periodontal therapy is tobacco regulations that prevent initiation of 
smoking, improve smoking cessation, and production of less addictive and toxic 
combustible tobacco products. Nevertheless, the future of periodontal therapy in 
smokers will be influenced by the growing populations of elderly with chronic 
periodontitis. As lifestyle and general health conditions might impair inflammatory 
host-responses, improved knowledge of smokers’ inflammatory responses will provide 
pertinent information in individualizing targeted therapies.  
Observed absence of local inflammatory responses to periodontal therapy in 
smokers may serve as a base for future research. It seems relevant to the ability of 
gingival fibroblasts to induce a prolonged and persistent local inflammatory cytokine 
production in smokers. Comparing inflammatory cytokines expressed in gingival 
fibroblasts derived from biopsies obtained from smokers and non-smokers, the impact 
of smoking on periodontal tissue response may be further elucidated. Identification of 
candidate genes or proteins in vitro, and determination of biological pathways that are 
affected by smoking, may provide important information of modulated local tissue 
responses in smokers. Moreover, fibroblasts derived from smokers and non-smokers 
may respond differently when exposed to periopathogenic bacterial species, to local 
expression of IL-8, and to high doses of cotinine.  
Another interesting area of investigation would be to evaluate differences in 
local and systemic inflammatory responses to periodontal therapy in smokers and non-
smokers. As smoking appears to stimulate an overall systemic hyper-inflammatory 
condition, comparisons of changes in systemic responses in smokers and non-smokers 
following periodontal therapy are warranted. Moreover, contextualized within 
suppressed local inflammatory responses, comparisons of local and systemic 
inflammatory responses to periodontal therapy appear critical in the search for 
biomarkers capable of resolving inflammatory processes in smokers and 
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Abstract
Aim: To evaluate the effect of smoking at patient, tooth, and site level following
non-surgical and surgical periodontal therapy.
Material and Methods: Eighty chronic periodontitis patients, 40 smokers and 40
non-smokers, were recruited to this single-arm clinical trial. Smoking status was
validated by measuring serum cotinine levels. Periodontal examinations were
performed at baseline (T0) and 3 months following non-surgical and surgical peri-
odontal therapy (T1). At T0 and T1, subgingival plaque samples were collected
from the deepest periodontal pocket in each patient and analysed using checker-
board DNA–DNA hybridization. Probing depth (PD) ≥ 5 mm with bleeding on
probing (BoP) was defined as the primary outcome. Unadjusted and adjusted
logistic regression analyses, corrected for clustered observations within patients
and teeth, were conducted comparing smokers with non-smokers.
Results: Clinical parameters significantly improved in both groups (p < 0.001).
An association was revealed between smoking and PD ≥ 5 mm with BoP (OR=
1.90, CI: 1.14, 3.15, p = 0.013), especially for plaque-positive sites (OR= 4.14, CI:
2.16, 7.96, p < 0.001). A significant reduction of red complex microbiota was
observed for non-smokers only (p = 0.010).
Conclusion: Smokers respond less favourably to non-surgical and surgical
periodontal therapy compared with non-smokers, in particular at plaque-positive
sites.
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Cigarette smoking appears a consid-
erable behavioural risk factor for
periodontal diseases (Albandar
2002). Depending on the definition
of the disease and exposure to smok-
ing, a smoker has 3–25 times higher
risk of developing chronic periodon-
titis compared with non-smokers
(Bergstr€om 2003, Hyman & Reid
2003). Nearly half of the cases diag-
nosed with chronic periodontitis are
smokers (Tomar & Asma 2000,
Hyman & Reid 2003, Do et al.
2008). In perspective, there is a
globally increasing prevalence of
cigarette smokers (Samet & Wipfli
2010, Ng et al. 2014).
Chronic periodontitis patients
generally respond favourably to con-
ventional periodontal treatment.
However, several studies indicate
that smokers respond less favourably
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both to non-surgical (Preber &
Bergstr€om 1986, Apatzidou et al.
2005, Wan et al. 2009) and surgical
approaches (Trombelli et al. 1997,
2003, Scabbia et al. 2001). In spite
of this, smokers are in general
treated following similar protocols as
for non-smokers.
Cigarette smoking is considered
an extrinsic modifying factor in the
pathogenesis of periodontal diseases
interacting with the host cells and
affecting the inflammatory response
to microbial challenge (Palmer et al.
2005). Plausible pathognomonic
mechanisms include impaired
neutrophil function, decreased lym-
phocyte proliferation and IgG
production, altered release of cytoki-
nes (Al-Shammari et al. 2001, Orbak
et al. 2003, Persson et al. 2003,
Apatzidou et al. 2005), reduced
revascularization, and decreased
fibroblast proliferation, attachment
and collagen synthesis (Gamal &
Bayomy 2002, Mavropoulos et al.
2007, Semlali et al. 2011). Smokers
also harbour increased levels of
putative periodontal pathogens com-
pared with non-smokers (Haffajee &
Socransky 2001b, Van Winkelhoff
et al. 2001, Guglielmetti et al. 2014,
Joshi et al. 2014). Interestingly, the
periodontal microbiota in smokers
may return to normal within 6–
12 months following smoking cessa-
tion (Fullmer et al. 2009).
The compromising effect of cigar-
ette smoking on periodontal therapy
appears dose-dependent (Kaldahl
et al. 1996, Rieder et al. 2004). Thus,
an objective estimation of smoking
status emerges as an important
prerequisite to identify and assess any
harmful effects of smoking on the
periodontium at a patient, tooth, and
site level (Scott et al. 2001, Kotsakis
et al. 2015). The use of self-reported
smoking data is prone to bias in indi-
viduals who often are unwilling to
disclose their smoking status. There-
fore, self-reported smoking status
needs to be objectively validated.
Besides the systemic effect, smok-
ing may also exert local effects. Pala-
tal sites and molar teeth seem to be
more susceptible to advanced attach-
ment loss throughout disease
progression (Haffajee & Socransky
2001a). To predict the outcome of
periodontal therapy in smokers, the
effect of smoking needs to be
explored at patient, tooth, and site
level. As variations in periodontal
treatment outcomes to a great extent
are explained by factors acting at a
site level (D’Aiuto et al. 2005, Kim
et al. 2007), the application of statis-
tical models analysing sites, taking
the clustering of data over teeth and
patients into account, appears
appealing. Focusing on the effects at
particular sites may provide a more
accurate explanation of the natural
hierarchical structure of the
treatment responses following peri-
odontal therapy.
There seem to be no prospective
studies evaluating the effect of
cigarette smoking on the outcomes
of non-surgical and surgical peri-
odontal treatment at site level in
chronic periodontitis patients, cor-
rected for clustered observations.
The overall purpose of this study
was to compare the initial periodon-
tal treatment outcome in smokers
and non-smokers. More specifically,
the aims were to evaluate the effect
of smoking at patient, tooth, and
site level following non-surgical and
surgical periodontal therapy and to
compare differences in the composi-
tion of the subgingival microflora
during treatment at the patient
level.
Material and Methods
Pre-study protocols and tests
The study protocol and informed
consent approved by the Institu-
tional Medical Research Ethics
Committee (2011/151-6), University
of Bergen, Norway followed the Hel-
sinki Declaration of 1975, version
2008. Prior to inclusion, all patients
read and signed a written consent
form.
Intra-examiner calibration
A calibration exercise was performed
to obtain intra-examiner repro-
ducibility for the clinical outcome
variable probing depth (PD) and
clinical attachment level (CAL). In a
sample of 10 subjects, PD and CAL
were measured twice, 1 day apart, at
six sites per tooth and the intraclass
correlation coefficients (ICC) were
calculated separately for each site.
The ICC ranged between 0.92 and
0.96 for PD and between 0.93 and
0.96 for CAL.
Sample size
The sample size estimation was
based on change in PD. A difference
of 0.5 mm from T0 to T1 was con-
sidered clinically relevant. Standard
deviation of the differences between
repeated PD measurements from the
intra-calibration exercise was
0.5 mm. A power analysis based on
40 subjects per group and with the
level of significance (a) set to 0.05,
gave an 88% power to detect a true
difference of 0.5 mm.
Blinding of the operator
The clinical examiner (DFB) was
tested towards the smoking status of
a sample of 30 chronic periodontitis
patients, 16 smokers (>10 cigarettes/
day for at least 5 years) and 14
non-smokers (never or not in the last
5 years). Calculus, plaque, and stain-
ing were removed and after rinsing
with 0.2% chlorhexidine gluconate
(Corsodyl, GlaxoSmithKline, Lon-
don, UK) for 1 min, the examiner,
wearing a face mask, scored the
smoking status as yes or no.
Twenty-eight patients (93%) were
correctly identified as either non-
smokers or smokers (p < 0.001).
Study group
Eighty patients, 40 smokers and 40
non-smokers, with moderate to
severe chronic periodontitis
(Armitage 1999) referred for peri-
odontal treatment from general
practitioners in a rural district of
Norway, were enrolled in this sin-
gle-arm clinical trial March 2012
through September 2013 (Table 1).
A detailed medical, dental, peri-
odontal, and smoking history for
the patients was obtained from
clinical examinations (including
weight and height registrations),
health forms, questionnaires, and by
consulting their physicians. Further-
more, they were examined for eligi-
bility and consecutively invited to
participate.
The inclusion criteria were
healthy subjects between 35 and
75 years, with no medication that
could affect periodontal healing,
having at least four non-adjacent
teeth with inter-proximal PD
≥ 6 mm and clinical attachment loss
≥5 mm, bleeding on probing (BoP),
and no signs of apical pathology
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(Tonetti & Claffey 2005, Page & Eke
2007). The subjects were either
smokers (>10 cigarettes/day for at
least 5 years) or non-smokers (never
or not in the last 5 years). Exclusion
criteria were any current medical
condition affecting periodontal treat-
ment and the use of systemic antibi-
otics or subgingival scaling in the
6 months before initiation of the
study.
Smoking status
The subjectively reported smoking
status was calculated in pack years;
the number of cigarettes smoked
daily multiplied by the number of
years divided by 20 (a standard pack
of cigarettes) (Scott et al. 2001).
Before treatment, smoking status
was objectively validated by measur-
ing cotinine levels in serum. Periph-
eral venous blood was collected from
each participant in a glass vacu-
tainer. After coagulation, blood was
centrifuged (1000 rpm/10 min) and
the serum was stored in aliquots at
80°C. Serum cotinine was assessed
according to the instructions of the
serum enzyme immunoassay kit
(Cotinine ELISA Kit, MyBioSource,
San Diego, USA) by measuring the
absorbance at 450 nm with a
microplate reader (FluoStar Optima
V1.32 R2, BMG Labtech, Offen-
burg, Germany).
Treatment
Non-surgical and surgical periodontal
treatment was performed by one
operator (DFB). All patients were
subjected to non-surgical treatment
consisting of motivation and instruc-
tion in oral hygiene and debridement
using hand instrumentation
(Hu-Friedy, Chicago, IL, USA; and
American Eagle Instruments, Mis-
soula, MT, USA) under local anaes-
thesia. Teeth with hopeless prognosis
were extracted during the non-surgi-
cal treatment phase (Mcguire 1991).
Each treatment session lasted
60–90 min and mean number of treat-
ment sessions was 5.5 for smokers
and 5.0 for non-smokers. The smok-
ers were motivated for smoking cessa-
tion and encouraged to participate in
a public smoking cessation program
(Røyketelefonen, Helsedirektoratet,
Oslo, Norway). Sixteen patients
(40%) accepted. After a healing per-
iod of 8 weeks, re-evaluation was per-
formed (Segelnick & Weinberg 2006).
To further reduce PD and inflamma-
tion in patients presenting PD >5 mm
with BoP and exhibiting adequate
oral hygiene routines, periodontal
surgery was implemented. Sixty-five
patients, 35 smokers and 30 non-
smokers, received periodontal surgery
(Fig. 1). Mean number of surgeries
per patient was 2.0 for smokers and
1.8 for non-smokers. Both periodon-
tal flap and gingivectomy techniques
were used following standard proto-
cols. Sutures and periodontal dress-
ings were removed at 7–10 days. A
0.2% chlorhexidine gluconate rinse
(Corsodyl, GlaxoSmithKline, Lon-
don, UK) was implemented for
4 weeks postsurgery. Postsurgical
controls, including full mouth plaque
removal and oral hygiene instruction,
were conducted every second or third
week until clinical evaluation at
12 weeks.
Clinical assessment
Before clinical examination, a full
mouth series of intra-oral radiographs
was taken. Clinical measurements
were registered at baseline pre-treat-
ment (T0) and at 3 months post-treat-
ment (T1). PD was recorded as the
distance in mm from the gingival mar-
gin to the probeable base of the
pocket, and CAL as the distance in
mm from the cemento-enamel junc-
tion or the margin of a dental restora-
tion to the probeable base of the
pocket. PD and CAL were measured
with a manual periodontal probe
(PCPUNC 15, Hu-Friedy, Chicago,
IL, USA) at six sites per tooth round-
ing up to the nearest mm. Full mouth
gingival bleeding was recorded as the
percentage of sites showing bleeding
after gentle probing (Ainamo & Bay
1975) and full mouth dental plaque as
the percentage of tooth surfaces with
visible plaque following staining with
disclosing solution (O’Leary et al.
1972). As a supplement to staining,
the periodontal probe was used to dis-
criminate between plaque and pellicle.
Microbiological assessment
At T0, two sterile paper points were
inserted into the deepest periodontal
pocket in each patient, and the
procedure was repeated at the same
site at T1. Before sampling, the site
was carefully cleaned of supragingival
Table 1. Baseline (T0) patient characteristics by smoking status. Frequency/distribution of







<60 years 19/47.5 18/45 0.727
≥60 years 21/52.5 22/55
Gender (n/%)
Male 15/37.5 23/57.5 0.121
Female 25/62.5 17/41.5
Marital status (n/%)
Married or cohabitant 24/60.0 35/87.2 0.011
Single 16/40.0 5/12.8
Income (n/%)
Yes 18/45.0 28/70.0 0.069
No 22/55.0 12/30.0
Education (n/%)
≤9 years 30/75.0 20/50.0 0.025
>9 years 10/25.0 20/50.0
Satisfaction with oral health (n/%)
Content 10/25.6 14/35.9 0.368
Neither discontent or content, or discontent 28/74.4 25/64.1
BMI (mean  SD) 24.3 (4.1) 25.7 (2.9) 0.112
Number of teeth present (mean  SD) 23.4 (5.2) 25.1 (2.9) 0.069
BI (mean  SD) 66.7 (18.2) 67.3 (15.7) 0.865
PI (mean  SD) 54.6 (21.9) 57.1 (20.3) 0.610
PD (mean  SD) 3.8 (1.5) 3.4 (1.4) 0.028
CAL (mean  SD) 4.6 (1.8) 4.0 (1.5) <0.001
BMI, body mass index; BI, bleeding index; PI, plaque index; PD, probing depth; CAL, clin-
ical attachment level.
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plaque and kept dry. The paper
points were gently inserted towards
the apex of the pocket and kept in
place for 20 sec (Renvert et al. 1992,
Belibasakis et al. 2014) before
removal and immersion into a pre-re-
duced sterile transport medium
(PRAS Dental Transport Medium,
Morgan Hill, CA, USA). The sample
tubes were analysed at Microbiologi-
cal Diagnostic Service, Department
of Oral Biology, Faculty of Dentistry,
University of Oslo, Oslo, Norway by
DNA-DNA hybridization (checker-
board technique) (Socransky et al.
2004). The results were reported sepa-
rately for each sample, showing both
qualitative and quantitative results.
Analysis included detection of red
(Porphyromonas gingivalis, Tre-
ponema denticola, and Tannerella for-
sythia) and orange (Prevotella
intermedia, Prevotella nigrescens, Fu-
sobacterium nucleatum subsp polymor-
phum, Fusobacterium nucleatum subsp
nucleatum, Fusobacterium nucleatum
subsp vincentii, and Parvimonas micra)




Normality assumptions of the contin-
uous variables were performed using
the skewness and kurtosis test.
Descriptive statistics were executed
using frequencies and percentage for
qualitative variables (chi-square test)
and mean  standard deviation for
quantitative variables (ordinary two
sample t-test and Mann–Whitney
test).
PD ≥5 mm with BoP, defined as
the primary outcome variable, was
dichotomized as (1) present and (0)
absent. In the logistic regressions each
site, corrected for clustering of the
data within teeth and patients, was
the unit of the analysis. Patient-re-
lated explanatory variables were
tested in unadjusted models and in a
multiple model adjusted for covari-
ates. In the analysis, time was catego-
rized as T0 (0) and T1 (1), age as
˂60 years (0) and ≥60 years (1), gen-
der as male (0) and female (1), self-re-
ported education as ≥9 years (0) and
<9 years (1), marital status as living
alone (0) and married/cohabitant (1),
and number of teeth at T0 < 15 teeth
(0) and ≥15 teeth (1). For each patient
an overall mean value for PD, CAL,
BI, and PI was calculated at T0. This
measure was applied to adjust for
heterogeneity at T0. Sites presenting
PD ≥5 mm with BoP at teeth
extracted between T0 and T1
were not included in the analysis.
Odds ratios (OR) and 95% confi-
dence intervals (95% CI) were calcu-
lated.
Secondary outcome variables,
changes in plaque index (PI), bleed-
ing index (BI), PD, and amount
of bacteria, were analysed by
conventional regression analysis, cor-
rected for clustered observations. A
p-value of less than 0.05 was consid-
ered statistically significant. All anal-
yses were conducted using Stata
version 13 (Stata Corp., College Sta-
tion, TX, USA).
Results
Patient characteristics are summa-
rized in Table 1. Eighty patients
were included; 40 smokers [mean age
57.6 years (range 37–70)] and 40
non-smokers [mean age 58.7 years
(range 35–73)]. Seventy-five patients
(94%) completed the study. During
treatment, significantly more teeth
with hopeless prognosis were
extracted in the smoking group
(p = 0.009); 37 teeth in 16 smokers
and 11 in nine non-smokers. In both
groups mean PD, plaque, and bleed-
ing index were significantly reduced
(p < 0.001) with no differences
between the groups at T0 or T1. In
smokers, mean PD was reduced
from 3.8 to 2.6 mm (1.2 mm) and in
non-smokers from 3.4 to 2.3 mm
(1.1 mm). Figure 2 presents mean
percentage of sites showing PD
reduction of one mm or more
between T0 and T1 for each PD
category for smokers and non-smo-
kers. Compared with non-smokers,
smokers demonstrated between 5 %
and 8 % less number of sites with
mm reduction for PD categories
between four and nine mm.
The distribution of PD ≥5 mm
with BoP, at T0 and T1 is summa-
rized in Table 2. At T0, smokers
presented with 1471 (26%) and non-
smokers with 1049 (18%) sites with
PD ≥5 mm and BoP. The numbers
decreased to 132 (3%) sites for
smokers and 52 (1%) sites for non-
smokers at T1. At the patient level,
the mean number of sites with PD
≥5 mm and BoP per smoker was
36.8 (26%) and 26.3 (18%) per non-
smoker at T0 (not tabulated). The
corresponding estimates at T1 were
3.47 (3%) and 1.41 (1%). At T1 no
patients in the non-smoking group
presented with more than seven sites
with PD ≥5 mm with BoP, whereas
five smokers exhibited 10 or more
sites. These five patients were all
heavy smokers with a mean cotinine
level of 725 ng/ml (range 501–861).
Mean cigarette consumption in the
smoking group was 37 pack years
(20–108) and mean cotinine level
471 ng/ml (range 168–861). No
patients reported starting or quitting
smoking during the study.
Non-surgical and surgical periodontal treatment (T0 - T1)
Dropouts
Lost to follow-up (compliance) 
n = 1 (non-smoker)
Discontinued intervention (systemic 
antibiotic)
n = 4 (2 smokers, 2 non-smokers)
Non-surgical and surgical therapy
n = 65 (35 smokers, 30 non-smokers)
Months (mean) between T0 and T1 = 7.9
(7.6 smokers, 8.3 non-smokers)
Non-surgical therapy
n = 10 (3 smokers, 7 non-smokers)
Months (mean) between T0 and T1 = 4.7
(5.9 smokers, 4.1 non-smokers)
T0 
n = 80 (40 smokers, 40 non-smokers)
T1 
n = 75 (38 smokers, 37 non-smokers)
Extracted teeth
n = 62 (45 smokers, 17 non-smokers)
Fig. 1. Study flow chart.
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Between T0 and T1 a higher
number of sites with PD ≥5 mm
with BoP was removed by tooth
extraction in the smoking compared
with the non-smoking group
(p = 0.002); 177 and 46 sites, respec-
tively. These sites were excluded
from the analysis. Compared with
non-smokers, an overall significantly
higher risk was found in smokers to
present with PD ≥5 mm with BoP at
T1 [OR = 2.01, CI: 1.24, 3.23,
p = 0.004 (not tabulated)]. The
adjusted analysis withstands the sig-
nificant association with smoking
and PD ≥5 mm with BoP at T1
[OR = 1.90, CI: 1.14, 3.15,
p = 0.013 (not tabulated)]. Results
of unadjusted and adjusted logistic
regression analysis of PD ≥5 mm
with BoP are presented in Table 3.
For both smokers and non-smokers
the unadjusted analysis showed sig-
nificant associations between PD
≥5 mm with BoP and mean T0 val-
ues of PD, CAL, and BI. For
smokers, a significant association
was shown for mean number of
teeth at T0. For both groups the
adjusted analysis revealed significant
associations between PD ≥5 mm
with BoP and mean baseline values
of PD, BI, and number of teeth.
For smokers only, CAL at T0 and
not living alone showed significant
associations with the primary out-
come.
Plaque-positive and plaque-
negative sites were analysed for the
association of PD ≥5 mm with BoP
in the adjusted model, with plaque-
negative sites in non-smokers as ref-
erence category. Plaque-positive sites
in smokers had an overall higher risk
to present with PD ≥5 mm with BoP
at T1 compared with plaque-positive
sites in non-smokers [4.14, CI:2.16,
7.96, p < 0.001 and OR:3.09,
CI:1.65, 5.79, p ˂ 0.001, respectively
(not tabulated)]. Further, within
arch, teeth, and site, a highly signifi-
cant effect of plaque was found with
an interaction between plaque and
smoking (Table 4). Presence of pla-
que more than doubled the risk of
having PD ≥5 mm with BoP in
smokers compared with non-smokers
(OR= 4.98, CI: 2.50, 9.93, p < 0.001
and OR = 2.40, CI: 1.09, 5.30,
p = 0.030, respectively) at maxillary
molar palatal sites.
Figure 3 shows number of
patients harbouring target microbial
species at T0 and T1. Mean sample
site PDs did not differ between smok-
ers and non-smokers at T0 (7.4 mm)









4 mm 5 mm 6 mm 7 mm 8 mm 9 mm
Baseline values of PD 
% Smokers Non-smokers
Fig. 2. Mean percentage of sites showing probing depth reduction of one mm or more
between T0 and T1 for each probing depth category.














Overall 1471 (26.4) 1049 (17.5) <0.001 132 (2.6) 52 (1.0) <0.001
Maxilla 894 (32.9) 638 (20.9) <0.001 78 (3.2) 32 (1.2) <0.001
Buccal 345 (26.4) 260 (17.1) 0.001 26 (2.1) 9 (0.7) 0.002
Palatal 549 (40.4) 378 (24.8) <0.001 52 (4.3) 23 (1.7) 0.001
Multi-rooted 306 (46.4) 334 (40.1) 0.159 37 (7.1) 22 (3.1) 0.017
Buccal 131 (39.7) 136 (32.6) 0.105 10 (3.8) 7 (2.0) 0.209
Palatal 175 (53.0) 198 (47.5) 0.309 27 (10.2) 15 (4.2) 0.009
Single-rooted 588 (28.5) 304 (13.7) 0.110 41 (2.1) 10 (0.8) 0.045
Buccal 214 (20.8) 124 (11.2) 0.680 16 (1.7) 2 (0.2) 0.121
Palatal 374 (46.4) 180 (16.2) 0.030 25 (2.6) 8 (0.8) 0.159
Mandibula 577 (20.3) 411 (13.9) 0.009 54 (2.1) 20 (0.7) 0.013
Buccal 253 (17.8) 181 (12.3) 0.027 23 (1.7) 9 (0.7) 0.029
Palatal 324 (22.7) 230 (15.6) 0.009 31 (2.4) 11 (0.8) 0.028
Multi-rooted 236 (35.8) 211 (30.6) 0.236 21 (3.5) 16 (2.6) 0.538
Buccal 99 (30.0) 86 (24.9) 0.269 9 (3.0) 7 (2.3) 0.617
Lingual 137 (41.5) 125 (36.2) 0.326 12 (4.0) 9 (2.9) 0.561
Single-rooted 341 (15.6) 200 (8.9) 0.013 33 (1.6) 4 (0.4) 0.191
Buccal 154 (14.1) 95 (8.4) 0.148 14 (1.4) 2 (0.2) 0.628
Lingual 187 (17.1) 105 (9.3) 0.011 19 (1.9) 2 (0.2) 0.190
BoP; bleeding on probing; multi-rooted, molars; single-rooted, premolars and incisors; buccal, two proximal-buccal and one mid-buccal;
palatal, two proximal-palatal and one mid-palatal; lingual, two proximal-lingual and one mid-lingual.
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quantitative reduction was observed
for the red (p = 0.35) and orange
(p = 0.16) complex species in the
smoking group (not tabulated). Nev-
ertheless, a significant reduction of
T. forsythia (p = 0.038), P. nigrescens
(p = 0.035), and F. nucleatum subsp
vincentii (p < 0.001) was detected.
Among non-smokers a significant
reduction was observed for the red
complex species (p = 0.010), specifi-
cally for P. gingivalis (p = 0.013) and
T. forsythia (p = 0.005). The orange
complex species showed a borderline
significant reduction (p = 0.060) with
a significant reduction of P. interme-
dia (p = 0.008), P. nigrescens
(p = 0.004), and F. nucleatum subsp
polymorphum (p = 0.035). However,
differences detected comparing single
species were considered inconclusive
due to multiple testing.
Discussion
This prospective study appears to be
the first to compare the effect of
non-surgical and surgical periodontal
therapy in smokers and non-smokers
using clinical and microbiological
parameters and an objective valida-
tion of self-reported smoking habits.
In both the smoking and non-smok-
ing groups, PD, BI, and PI improved
significantly following treatment. PD
categories between 4 and 8 mm
showed a less reduction in smokers
compared with non-smokers. In per-
spective, Tomasi reported a 30%
reduction in pocket closure in smok-
ers following non-surgical periodon-
tal therapy with a more limited
effect in initially deep pockets (To-
masi et al. 2007). The present study
using the same PD categories con-
firms a less reduction in initially
deep pockets in smokers following
non-surgical and surgical treatment.
The relatively high number of
patients receiving periodontal sur-
gery was due to initially deep PDs in
patients exhibiting adequate oral
hygiene standards and good general
health. Cigarette smoking is not a
contraindication to periodontal sur-
gery, but high cigarette consumption
is considered a risk factor generating
less favourable clinical outcomes
(Matuliene et al. 2008). The negative
effects of cigarette smoking increase
in a non-linear consumption model
and patients consuming ≥ 20 cigar-
ettes per day are considered at high
risk for treatment relapse (Lang &
Tonetti 2003).
In the present study, the five
patients presenting with 10 or more
sites with PD ≥5 mm with BoP fol-
lowing treatment were all heavy
smokers with a mean serum cotinine
level of 725 ng/ml. The discrepancy
between measured cotinine level and
subjectively reported cigarette con-
sumption was more pronounced for
heavy smokers, indicating a higher
underreporting. A socioeconomic
stigma of smokers and pressure
towards smoking cessation, likely
make smokers susceptible to under-
reporting their smoking habits (Scott
et al. 2001, Stuber & Galea 2009).
This should be a concern for
clinicians in the everyday treatment
planning and in projecting prognosis
for teeth at risk in smokers.
The causality of cigarette smok-
ing on the outcomes of periodontal
treatment must be interpreted with
caution as smokers tend to present
with more advanced periodontitis
Table 3. Unadjusted and adjusted OR for PD ≥ 5 mm with BoP, stratified by smoking status
Characteristics Smokers Non-smokers
Unadjusted* Adjusted† Unadjusted* Adjusted†
OR 95% CI p OR 95% CI p OR 95% CI p OR 95% CI p
Time
T0 1 1 1 1
T1 0.17 0.13, 0.22 <0.001 0.086 0.06, 0.12 <0.001 0.085 0.06, 0.13 <0.001 0.041 0.03, 0.06 <0.001
Age
<60 years 1 1 1 1
≥60 years 0.93 0.62, 1.39 0.710 1.00 0.99, 1.01 0.350 0.75 0.48, 1.16 0.196 0.98 0.98, 0.99 <0.001
Gender
Male 1 1 1 1
Female 0.97 0.63, 1.50 0.904 0.88 0.74, 1.05 0.154 1.33 0.90, 1.98 0.152 1.03 0.84, 1.27 0.754
Education
≥9 years 1 1 1 1
<9 years 1.30 0.86, 2.00 0.208 1.07 0.89, 1.29 0.488 1.35 0.94, 1.95 0.106 0.87 0.71, 1.05 0.150
Marital status
Single 1 1 1 1
Co-habitant 1.04 0.70, 1.55 0.855 0.84 0.71, 0.98 0.027 1.40 0.88, 2.22 0.151 0.90 0.63, 1.28 0.545
Teeth at T0
˂15 teeth 1
≥15 teeth 0.95 0.92, 0.99 0.015 1.07 1.03, 1.10 <0.001 0.99 0.94, 1.05 0.806 0.96 0.94, 0.98 <0.001
PD, per mm increase 3.10 2.70, 3.56 <0.001 3.54 2.95, 4.24 <0.001 3.42 2.98, 3.92 <0.001 4.36 3.74, 5.09 <0.001
CAL, per mm increase 1.78 1.60, 1.99 <0.001 1.14 1.04, 1.26 0.007 2.17 1.93, 2.42 <0.001 1.02 0.87, 1.20 0.761
BI, per 10% increase 1.15 1.03, 1.27 0.009 1.09 1.05, 1.13 <0.001 1.29 1.16, 1.44 <0.001 1.14 1.07, 1.22 <0.001
PI, per 10% increase 1.07 0.96, 1.19 0.225 1.05 0.99, 1.10 0.083 1.10 1.00, 1.21 0.062 0.97 0.94, 1.01 0.115
BoP, bleeding on probing; CI, Confidence Interval; OR, Odds Ratio; PD, probing depth; CAL, clinical attachment level; BI, bleeding index;
PI, plaque index.
*Unadjusted logistic regression for PD ≥ 5 mm with BoP.
†Adjusted logistic regression for PD ≥ 5 mm with BoP, and time, age, gender, education, marital status, teeth at T0, and mean values of
PD, CAL, BI, and PI at T0. Sites with PD ≥ 5 mm with BoP extracted between T0 and T1 were not included in the analysis.
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(Hugoson & Rolandsson 2011). In
this study, an association between
smoking and PD ≥5 mm with BoP
was shown both with and without
baseline adjustments. This observa-
tion is consistent with a systematic
review on the influence of cigarette
smoking on the effect of non-surgi-
cal therapy (Labriola et al. 2005).
The negative effect of cigarette
smoking was shown by including
BoP in the primary outcome,
although smokers tend to have scar-
cer bleeding from deeper PDs than
non-smokers (Preber & Bergstr€om
1985). Excluding BoP might posi-
tively influence the primary outcome
in non-smokers by deeper probe
penetration into the inflamed soft
tissue at T0 and a more pronounced
shrinkage of gingiva during resolu-
tion of the inflammation (Biddle
et al. 2001). Further, BoP is consid-
ered an indicator for disease progres-
sion in high-risk patients at site level
and absence of BoP indicates a
lower risk for disease progression in
both smokers and non-smokers
(Lang et al. 1990, Claffey & Egel-
berg 1995).
A significant association was
detected between PD ≥5 mm with
BoP and presence of plaque, in
smokers as well as non-smokers.
This association was highly signifi-
cant for smokers and particularly
pronounced for maxillary molar
palatal sites. These sites are immedi-
ately exposed to cigarette smoke and
thereby to nicotine and combustion
products. Binding of nicotine and
tar to root surfaces and a 300 times
higher concentration of cotinine in
GCF compared with plasma, are
proposed causative factors for
impaired treatment response (Cuff
et al. 1989, Ryder et al. 1998, Wan
et al. 2009). Further, plaque control
being generally demanding in the
posterior dentition may increase the
probability of cigarette smoke aggra-
Table 4. Relative risks for PD ≥ 5 mm with BoP at arch, tooth, and site levels, with and without cigarette smoking and presence of plaque
following periodontal treatment. Reference category: plaque-negative sites in non-smokers
Localization Smokers plaque-negative sites Non-smokers plaque-positive sites Smokers plaque-positive sites
OR CI p OR CI p OR CI p
Maxilla 1.10 0.94, 1.29 0.224 2.21 1.22, 4.00 0.009 3.16 1.65, 5.90 <0.001
Mandibula 1.03 0.82, 1.30 0.783 7.12 2.47, 20, 52 <0.001 8.75 3.02, 25.33 <0.001
Multi-rooted 1.15 0.98, 1.37 0.097 2.92 1.51, 5.67 0.002 4.13 2.17, 7.87 <0.001
Single-rooted 1.01 0.81, 1.26 0.946 2.59 0.91, 7.38 0.075 3.96 1.51, 10.33 0.005
Buccal 1.04 0.85, 1.26 0.730 2.09 1.05, 4.18 0.037 3.07 1.47, 6.40 0.003
Palatal/lingual 1.08 0.91, 1.29 0.371 4.27 2.13, 8.56 <0.001 5.24 2.67, 10.30 <0.001
Teeth within arch
Maxilla
Multi-rooted 1.25 1.02, 1.53 0.029 1.64 0.84, 3.19 0.148 3.15 1.53, 6.49 0.002
Single-rooted 1.01 0.79, 1.29 0.921 2.87 0.99, 1.29 0.053 3.27 1.25, 8.51 <0.001
Mandibula
Multi-rooted 1.05 0.83, 1.32 0.712 12.64 4.12, 38.26 <0.001 10.87 4.18, 28.26 <0.001
Single-rooted 1.00 0.71, 1.39 0.996 2.04 0.44, 9.41 0.361 5.50 1.37, 22.00 0.016
Sites within arch
Maxilla
Buccal 0.99 0.80, 1.22 0.920 1.17 0.58, 2.36 0.665 2.00 0.89, 4.49 0.095
Palatal 1.21 0.99, 1.47 0.066 3.59 1.80, 7.14 <0.001 4.45 2.38, 8.33 <0.001
Mandibula
Buccal 1.15 0.82, 1.59 0.420 6.46 2.26, 18.53 0.001 7.79 2.54, 23.85 <0.001
Lingual 0.97 0.71, 1.33 0.844 7.66 2.19, 26.83 0.001 9.37 2.84, 30.97 <0.001
Sites within multi-rooted teeth
Maxilla
Buccal 1.31 1.01, 1.72 0.045 0.98 0.45, 2.13 0.964 1.54 0.50, 4.79 0.456
Maxilla
Palatal 1.21 0.92, 1.58 0.180 2.40 1.09, 5.30 0.030 4.98 2.50, 9.93 <0.001
Mandibula
Buccal 1.16 0.76, 1.77 0.503 11.41 3.04, 42.77 <0.001 9.88 3.01, 32.39 <0.001
Mandibula
Lingual 0.96 0.70, 1.33 0.823 15.10 4.60, 49.61 <0.001 12.69 4.27, 37.73 <0.001
Sites within single-rooted teeth
Maxilla
Buccal 0.85 0.61, 1.19 0.337 1.17 0.26, 5.17 0.840 2.85 0.87, 9.32 0.083
Maxilla
Palatal 1.13 0.86, 1.48 0.390 5.05 1.47, 17.34 0.010 3.56 1.31, 9.67 0.013
Mandibula
Buccal 1.08 0.72, 1.61 0.709 2.44 0.48, 12.54 0.284 5.26 1.10, 25.23 0.038
Mandibula
Lingual 0.96 0.61, 1.51 0.871 1.78 0.31, 10.42 0.521 5.17 1.23, 21.58 0.024
BoP, bleeding on probing; CI, confidence interval; OR, odds ratio; multi-rooted, molars; single-rooted, premolars and incisors; palatal, mesio-
palatal and palatal and disto-palatal; lingual, mesio-ling and lingual and disto-lingual; buccal, mesio-buccal and buccal and disto-buccal.
Logistic regression with outcome PD ≥ 5 mm with BoP adjusted for time, age, gender, education, marital status, mean PD, CAL, BI, BI,
and number of teeth present at T0. Sites with PD ≥ 5 mm with BoP extracted between T0 and T1 were not included in the analysis.
© 2015 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd
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vating a plaque-induced inflamma-
tory process.
An increased presence of red
and orange complex species was
found in smokers compared with
non-smokers at T0 and T1. The
non-significant reduced counts in
the red and the orange complex
species, especially P. gingivalis and
T. denticola in smokers, are in
agreement with previous reports
(Grossi et al. 1997, Haffajee et al.
1997). In the present study, all
smokers maintaining elevated red
complex bacterial counts at T1
were heavy smokers. In perspective,
early dysbiosis in subgingival pla-
que colonization is influenced by
cigarette smoke and in a dose
responding manner (Hutcherson
et al. 2015). P. gingivalis has a
potential to enhance early plaque
formation in smokers (Bagaitkar
et al. 2011, Zeller et al. 2014).
Early microbial colonization and
poor correlation between the mar-
ginal and subgingival ecosystems in
smokers might further impair reso-
lution of inflammation during treat-
ment (Joshi et al. 2014). As plaque
formation adapts to cigarette smoke
and the alterations are reversed
when removing the cigarette stimu-
lus, it is critical to avoid smoking
exposure during periodontal ther-
apy. The ability of the microbiota
to adapt to tobacco exposure
should encourage further multilevel
investigation of clinical and micro-
biological effects of smoking cessa-
tion or reduction during
periodontal treatment.
We acknowledge that the lack of
blinding might be a limiting factor in
the present study. An attempt to
blind the operator with regard to
smoking status was unsuccessful. To
reduce bias, all data plotting was per-
formed by a person unaware of clini-
cal registrations and smoking status.
Moreover, personnel conducting the
microbiological analysis were blinded
to the smoking status of the patients.
To reduce the risk of treatment varia-
tion, all patients were treated by one
operator. The high-level oral hygiene
standards achieved might be influ-
enced by the Hawthorne effect, as
participants were aware of being part
of the study.
In conclusion, within limitations
of the study, smokers show less
favourable treatment response to
non-surgical and surgical periodontal
therapy in terms of residual PD
≥5 mm with BoP, reduced counts of
red and orange complex bacterial
species, and PD reduction. Elevated
smoking exposure negatively influ-
enced the number of PD ≥5 mm
with BoP and the microbial counts.
Correcting for clustered observations
within patients and teeth revealed an
increased risk for PD ≥5 mm with
BoP at plaque-positive sites in
smokers. Collectively, the results
demonstrate a site-specific tissue
response in smokers following initial
periodontal therapy superimposed
on a systemic effect.
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Scientific rationale for the study:
Generally, smokers respond less
favourable compared with non-
smokers to non-surgical and surgi-
cal periodontal therapy. To predict
the outcome of periodontal ther-
apy in smokers, the effect of
smoking needs to be critically
evaluated at patient, tooth, and site
level.
Principal findings: Smokers showed
impaired clinical and microbiological
responses to non-surgical and surgi-
cal periodontal therapy. At tooth
and site level, odds ratios for having
probing depth ≥5 mm with bleeding
on probing following treatment were
higher for smokers in all locations,
especially for plaque-positive sites.
Practical implications: Clinicians
should consider including smoking
cessation as a vital component of
treatment to optimize the effect of
non-surgical and surgical periodon-
tal therapy.
© 2015 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd





                    Study II 
Site-specific treatment outcome in smokers following 12 months of supportive 
periodontal therapy 
Bunæs DF, Lie SA, Åstrøm AN, Mustafa K, Leknes KN.  
Journal of Clinical Periodontology 2016;43(12):1086-93. 

Site-specific treatment outcome
in smokers following 12 months
of supportive periodontal therapy
Bunæs DF, Lie SA, Astrøm AN, Mustafa K, Leknes KN. Site-specific treatment
outcome in smokers following 12 months of supportive periodontal therapy. J Clin
Periodontol 2016; 43: 1086–1093. doi: 10.1111/jcpe.12619.
Abstract
Aim: To evaluate the effect of cigarette smoking on periodontal health at patient,
tooth, and site levels following supportive therapy.
Materials and Methods: Eighty chronic periodontitis patients, 40 smokers and 40
non-smokers, were recruited to a single-arm clinical trial. Periodontal examina-
tions were performed at baseline (T0), 3 months following active periodontal
therapy (T1), and 12 months following supportive periodontal therapy (T2).
Smoking status was validated measuring serum cotinine levels. Probing depth
(PD) ≥ 5 mm with bleeding on probing (BoP) was defined as the primary out-
come. Logistic regression analyses adjusted for clustered observations of patients,
teeth, and sites and mixed effects models were employed to analyse the data.
Results: All clinical parameters improved from T0 to T2 (p < 0.001), whereas
PD, bleeding index (BI), and plaque index (PI) increased from T1 to T2 in smok-
ers and non-smokers (p < 0.001). An overall negative effect of smoking was
revealed at T2 (OR = 2.78, CI: 1.49, 5.18, p < 0.001), with the most pronounced
effect at maxillary single-rooted teeth (OR = 5.08, CI: 2.01, 12.78, p < 0.001). At
the patient level, less variation in treatment outcome was detected within smokers
(ICC = 0.137) compared with non-smokers (ICC = 0.051).
Conclusion: Smoking has a negative effect on periodontal health following
12 months of supportive therapy, in particular at maxillary single-rooted teeth.
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Active periodontal therapy (APT)
followed by supportive periodontal
therapy (SPT) has been demon-
strated successful in a majority of
patients (Axelsson & Lindhe 1981,
Ramfjord 1987, Rosling et al. 2001,
Axelsson et al. 2004). In perspective,
patients susceptible to recurrence of
periodontal disease have been
offered SPT at 3- to 4-month inter-
vals with the intent to maintain
treatment outcomes following APT,
whereas less susceptible patients may
be well served, using a less frequent
SPT interval (Knowles et al. 1979,
Lindhe & Nyman 1984). To facilitate
identification of individuals at high
risk for disease progression, a func-
tional Periodontal Risk Assessment
(PRA) diagram has been proposed
(Lang & Tonetti 2003). In a longitu-
dinal study validating the PRA
model, patients allocated to the
high-risk category following APT
showed a higher incidence of tooth
loss compared with moderate- or
low-risk patients (Eickholz et al.
2008).
In spite of clinical benefits, only a
minority of patients appear to com-
ply with recommended SPT regimens
(Checchi et al. 1994, Demetriou
et al. 1995), and efforts to optimize
compliance being only partly suc-
cessful (Wilson et al. 1993). Further,
it appears that SPT compliance
decreases as the risk profile of the
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subject increases (Mendoza et al.
1991, Matuliene et al. 2010). Because
of imperfect outcomes following
APT (Bunæs et al. 2015) and incon-
sistent compliance (Matuliene et al.
2010, Ramseier et al. 2014), the
selection of appropriate SPT inter-
vals is of paramount importance for
the maintenance of periodontal sta-
bility in cigarette smokers.
Smoking is a critical patient-
related risk factor for chronic peri-
odontitis and smokers exhibit fewer
teeth and more advanced periodon-
tal attachment loss compared with
non-smokers (Kerdvongbundit &
Wikesjo 2000, Calsina et al. 2002,
Jansson & Lavstedt 2002). High
cigarette consumption amplifies clini-
cal manifestations of chronic peri-
odontal disease and demands
increased treatment needs (Dietrich
et al. 2004, Susin et al. 2004, Do
et al. 2008, Ramseier et al. 2015).
Based on subjectively reported pack-
year consumption, dose-dependent
impaired clinical outcomes following
SPT have been reported (Kaldahl
et al. 1996a). It is unclear to what
extent treatment response is influ-
enced by a cumulative impact of
smoking over years or by the con-
sumption during SPT. However, a
positive effect of smoking cessation
on periodontal treatment outcomes
may indicate the effect of present
smoking exposure (Preshaw et al.
2005, Rosa et al. 2011).
Generally, optimal soft and hard
tissue healing following APT is a
critical point for successful treatment
outcome. In a recently published
study, Bunæs et al. (2015) reported
impaired site-specific tissue responses
to non-surgical and surgical APT in
smokers compared with non-smo-
kers. The multilevel approach using
probing depth (PD) with bleeding on
probing (BoP) as the primary out-
come variable showed that plaque
positive sites increased the risk for
unfavourable treatment outcomes in
smokers. A local additive detrimen-
tal effect of smoking is supported by
studies reporting increased incidence
of oral cancer and altered composi-
tion of the oral biofilm (Haffajee &
Socransky 2001, Hashibe et al. 2007,
Guglielmetti et al. 2014).
Longitudinal cohort studies have
reported that smoking 20 or more
cigarettes a day increased the risk of
disease progression following APT
(Kaldahl et al. 1996a, Matuliene
et al. 2008). In contrast, long-term
follow-up studies have not found an
association between smoking status
and tooth loss (Fisher et al. 2008,
Saminsky et al. 2015). These incon-
clusive findings indicate that the
effect of subjectively reported smok-
ing habits on the outcome of SPT
needs to be addressed in a prospec-
tive study with an objective measure
of smoking exposure.
To the best of our knowledge,
there seems to be no prospective
studies evaluating the patient, tooth,
and site-related effects of cigarette
smoking on the outcome of SPT in
chronic periodontitis patients, using
an objective measure of smoking sta-
tus. Thus, the specific aims of this
study were to determine the effect of
smoking at patient, tooth, and site
levels following 12 months of SPT
and to compare the predictive value
of clinical parameters for the out-
come of SPT in smokers and non-
smokers.
Material and Methods
The study protocol and informed
consent approved by the Institu-
tional Medical Research Ethics
Committee (2011/151-6), University
of Bergen, Norway, followed the
Helsinki Declaration of 1975, ver-
sion 2008. Participating subjects read
and signed the informed consent
prior to inclusion in the study.
Pre-study tests
Two pre-study exercises were per-
formed. First, the intra-examiner
(DFB) reproducibility was tested by
measuring PD and clinical attach-
ment levels (CAL) twice at six sites
per tooth in 10 patients. Intra-class
correlation coefficients (ICC) for
repeated measures ranged between
0.92 and 0.96 for PD and between
0.93 and 0.96 for CAL. The sample
size estimation was based on change
in PD. A difference of 0.5 mm was
considered clinically relevant. Stan-
dard deviation of the differences
between repeated PD measurements
from the intra-calibration amounted
to 0.5 mm. A power analysis based
on 40 subjects per group and with
the level of significance (a) set to
0.05, gave an 88% power to detect a
true difference of 0.5 mm. Second,
masking of the operator (DFB)
towards smoking status was tested in
30 chronic periodontitis patients.
Twenty-eight of 30 patients (93%)
were correctly identified as smokers
or non-smokers (p < 0.001; for detail
see Bunæs et al. 2015).
Eligibility criteria, patient sample, and
smoking status
Inclusion criteria were healthy sub-
jects aged 35–75 years, none using
medication that could affect peri-
odontal healing, having at least four
non-adjacent teeth with an inter-
proximal PD ≥ 6 mm and clinical
attachment loss ≥5 mm with BoP
without signs of apical pathology
(Tonetti & Claffey 2005, Page & Eke
2007). The patients were either
smokers (>10 cigarettes/day for at
least 5 years) or non-smokers (never
or not smoked within the last
5 years). Patients starting or discon-
tinuing smoking during the study
were not excluded. Exclusion criteria
included any current medical condi-
tion affecting periodontal treatment,
use of systemic antibiotics or subgin-
gival scaling within 6 months prior
initiation of the study, and delay of
scheduled treatment visits by more
than one month.
Eighty patients, 40 smokers and
40 non-smokers, with moderate to
severe chronic periodontitis (Armi-
tage 1999) referred for periodontal
treatment from general practitioners
in a rural district of Norway were
consecutively enroled in this single-
arm clinical trial March 2012 through
September 2013 (Table 1). Medical,
periodontal, and smoking history of
the patients was obtained from clini-
cal examinations, health forms, ques-
tionnaires, and by consulting their
physicians. All referred patients were
examined for eligibility and consecu-
tively invited to participate.
The subjectively reported smoking
status was calculated in pack years;
the number of cigarettes smoked daily
multiplied by the number of years
divided by 20 (a standard pack of
cigarettes) (Scott et al. 2001). Before
and at the end of the study, smoking
status was objectively validated by
measuring cotinine levels in serum.
Peripheral venous blood was collected
from each participant using a glass
vacutainer. After coagulation, blood
was centrifuged (700 9 g for 10 min.)
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and the serum was stored in aliquots
at 80°C. Serum cotinine was
assessed according to the instructions
of the serum enzyme immunoassay
kit (Cotinine ELISA Kit; MyBio-
Source, San Diego, CA, USA) mea-
suring the absorbance at 450 nm with
a microplate reader (FluoStar Optima
V1.32 R2; BMG Labtech, Offenburg,
Germany).
Clinical assessments
A full-mouth intra-oral radiographs
series was recorded before the clinical
examination. Clinical recordings were
collected at baseline pre-ATP (T0), at
3 months post-APT (T1), and follow-
ing 12 months of SPT (T2). PD was
recorded as the distance from the gin-
gival margin to the probeable base of
the pocket, CAL as the distance from
the cemento-enamel junction or the
margin of a dental restoration to the
probeable base of the pocket. PD and
CAL were measured using a periodon-
tal probe (PCPUNC 15; Hu-Friedy,
Chicago, IL, USA) at six sites per
tooth rounding up to the nearest mm.
Full mouth gingival bleeding scores
were recorded as the percentage of
sites showing bleeding on gentle prob-
ing (Ainamo & Bay, 1975) and full
mouth dental plaque scores as the per-
centage of tooth surfaces with visible
plaque following staining with disclos-
ing solution (O’Leary et al. 1972). As
a supplement to staining, the peri-
odontal probe was used to discrimi-
nate between plaque and pellicle.
Treatment
APT (T0-T1) and SPT (T1-T2) were
performed by the same operator
(DFB). APT included nonsurgical
and surgical periodontal therapy
individualized to optimize treatment
outcomes for each patient. Follow-
ing ATP, a programme with regular
appointments every three months
was scheduled for SPT (Knowles
et al. 1979, Lindhe et al. 1984). The
60-min appointments included
re-motivation and re-instruction in
oral hygiene, full mouth plaque
removal, and supra- and subgingival
debridement as needed. In addition,
smokers were motivated to reduce or
quit smoking, and encouraged to
participate in a public smoking ces-
sation programme (Røyketelefonen,
Helsedirektoratet, Oslo, Norway).
Mechanical debridement was carried
out using conventional hand-instru-
ments (Hu-Friedy, Chicago, IL,
USA; and American Eagle Instru-
ments, Missoula, MT, USA) and
ultrasonic scalers (EMS, Nyon,
Switzerland). For plaque removal,
rotating rubber cups and glycine
powder (EMS – Air Flow-Perio) in
an air-polishing device (Dentsply
Prophy-Jet ; Dentsply, York, PA,
USA) were used.
Statistical analysis
The Shapiro–Wilk test was used to
check for the assumption of normal
distributed data. According to the
test, the data were considered nor-
mally distributed. Means and stan-
dard deviations of secondary
outcome variables (number of teeth,
PD, CAL, BI, PI) were calculated
and differences were tested, using the
two sample t-test and Mann–Whit-
ney test. Chi-square test was applied
for testing of differences in frequen-
cies and percentages between the cat-
egorical variables.
In an adjusted logistic regression
model, gender was categorized as
male (1) and female (0), age as
≥60 years (1) and ˂60 years (0), self-
reported education as ≤9 years (1)
and >9 years (0), and marital status
as married/cohabitant (1) and living
alone (0). The primary outcome vari-
able PD ≥ 5 mm with BoP was
dichotomized as (1) present and (0)
absent. Each site, corrected for clus-
tering of data within teeth and
patients, was the unit of analysis.
Sites presenting PD ≥ 5 mm with
BoP at teeth extracted between T0
and T1 were not included in the
analysis. Associations between
PD ≥ 5 mm with BoP at T2 and
clinical variables at T0 and T1 were
tested using adjusted logistic regres-
sion analysis. Plaque positive sites
categorized as (0) and plaque nega-
tive sites as (1), BoP positive sites as
(0) and BoP negative sites as (1),
and overall mean values calculated
at T0 and T1 for PD and CAL were
tested. For the smoking effect model
following T1, specific teeth and sites
were tested at T1 and T2. Two
dummy variables were made for time
and smoke and included in the
adjusted model: (T2 = 1 and Smoke
= 0) as (1) and (T2 = 1 and Smoke =
1) as (0) and (T1 = 1 and Smoke =
0) as (1) and T1 = 1 and Smoke = 1)
as (0). Intra-class correlation coeffi-
cients (ICC) within patients, teeth,
and sites were calculated using linear
mixed effects models.
Odds ratios (OR) and 95% confi-
dence intervals (95% CI) were calcu-
lated. A p-value <0.05 was
considered statistically significant.
All analyses were conducted using
Stata version 13 (Stata Corp., Col-
lege Station, TX, USA).
Results
Eighty patients, 40 smokers (mean
age 57.6 years, range 37–70 years)
and 40 non-smokers (mean age
58.7 years, range 35–73 years),
entered this study. Socio-demo-
graphic characteristics according to
smoking status at baseline (T0) are
summarized in Table 1. The experi-
mental protocol started April 2012
to end March 2015. Thirty-six (90%)
smokers and 36 (90%) non-smokers
completed the study (Fig. 1). Drop-
outs did not alter the socio-demo-
graphic characteristics at T1 and T2.







≥60 years/<60 years 21/19 (52.5/47.5) 22/18 (55.0/45.0) 0.096
Male/female 15/25 (37.5/62.5) 23/17 (56.0/44.0) 0.121
Cohabitant/single 24/16 (60.0/40.0) 35/5 (87.2/12.8) 0.011
Elementary school/education beyond 30/10 (75.0/25.0) 20/20 (50.0/50.0) 0.025
Working/not working 18/22 (45.0/55.0) 28/12 (70.0/30.0) 0.069
Satisfaction/dissatisfaction with oral
health
10/28 (26.3/73.7) 7/32 (18.0/82.1) 0.376
Alcohol consumption daily or weekly/
monthly or never
21/25 (58.3/41.7) 18/21 (46.2/53.9) 0.292
Dental visits regularly/irregularly 35/2 (94.6/5.4) 37/2 (94.9/5.1) 0.957
Students t-test and Chi-square: p-level <0.05.
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Three (7.9%) smokers reported dis-
continuing smoking between T1 and
T2, only one exhibited a cotinine




higher mean PD and CAL at all
time-points (Table 2). Between T0
and T2 both groups responded
favourable to periodontal therapy
with significant reductions in mean
PD, CAL, BI, and PI (p < 0.001)
(not tabulated). However, during
SPT, from T1 to T2, mean PD, BI,
and PI increased in both groups. In
smokers mean PD increased from
2.63 to 2.80 mm (p = 0.007) and in
non-smokers from 2.27 to 2.42 mm
(p = 0.002), BI in smokers from
22.42 to 27.00 (p = 0.011) and in
non-smokers from 22.81 to 30.50
(p = 0.001), and PI in smokers from
18.45 to 30.09 (p < 0.001) and in
non-smokers from 21.49 to 32.78
(p < 0.001) (not tabulated). From T1
to T2, mean CAL did not change
significantly in either smokers or
non-smokers (not tabulated).
An overall distribution of
PD ≥ 5 mm with BoP was 11.3% in
smokers and 7.1% in non-smokers.
In comparison, the corresponding
percentages for PD ≥ 5 mm only
were 14.8% in smokers and 8.3% in
non-smokers. Compared with non-
smokers, smokers had 4.2% more
number of sites with PD ≥ 5 mm
with BoP compared with 6.5% more
PD ≥ 5 mm. The number of sites
with PD ≥ 5 mm with BoP at T0,
T1, and T2 are summarized in
Table 3. At T1, the total number in
smokers were 132 (2.6%) and 52
(1.0%) in non-smokers (p < 0.001),
increasing at T2 to 180 (3.8%) in
smokers and 79 (1.6%) in non-smo-
kers (p < 0.001). From T1 to T2, the
increase was significant for all teeth
and sites in smokers and non-smo-
kers, except for multi-rooted buccal
sites in non-smokers. At T2, a higher
number of PD ≥ 5 mm with BoP
was observed in smokers compared
with non-smokers at maxillary molar
palatal sites (p = 0.040), at maxillary
single-rooted palatal and buccal sites
(p = 0.001 and p = 0.002, respec-
tively), and at mandibular single-
rooted lingual sites (p = 0.032).
Based on the number of
PD ≥ 5 mm with BoP, patients were
allocated into four different groups:
(1) patients with 0 sites; (2) patients
with 1–4 sites; (3) patients with 5-8
sites; and (4) patients with ≥9 sites.
For both smokers and non-smokers
at T0, 97.5% (n = 39) had ≥9 sites
and 2.5% (n = 1) 5-8 sites. For
smokers at T1, 13.2% (n = 5) had
≥9 sites, 13.2% (n = 5) 5-8 sites,
55.3% (n = 21) 1–4 sites, and 18.4%
(n = 7) had 0 numbers of
PD ≥ 5 mm with BoP (not tabu-
lated). At T2, the corresponding per-
centages were 16.7% (n = 6), 25.0%
(n = 9), 38.9% (n = 14), and 19.4%
(n = 7). For non-smokers at T1, 0
patients had ≥9 sites (group 4) and
8.1% (n = 3) had 5-8 sites (group 3)
and at T2, the respective percentages
were 2.8% (n = 1) and 13.9%
(n = 5). The mean level of three dif-
ferent cigarette measures was
recorded and presented for each
patient group at T0 and T2 (Fig. 2).
Compared with subjectively reported
Active (T0 -T1) and supportive (T1-T2) periodontal therapy
Dropouts
n= 5
Lost to follow-up (compliance) 
n = 1 non-smoker
Discontinued intervention 
(systemic antibiotic)
n = 4 (2 smokers, 2 non-smokers)
T0 
n = 80 (40 smokers, 40 non-smokers)
T1 
n = 75 (38 smokers, 37 non-smokers)
Dropouts
n = 3
Lost to follow-up 
n = 1 smoker (compliance)
n = 1 non-smoker (deceased)
Discontinued intervention (systemic 
antibiotic and compliance)
n = 1 smoker
T2
n = 72 (36 smokers, 36 non-smokers)
Extracted teeth
n = 48 (37 smokers, 11 non-smokers
Extracted teeth
n = 7 (4 smokers,3 non-smokers)
Fig. 1. Study flow chart.
Table 2. Patient-related clinical measures in smokers and non-smokers at T0, T1, and T2
Clinical
measures
















23.35 (5.14) 25.08 (2.88) 0.069 22.53 (5.65) 24.81 (3.30) 0.036 22.11 (6.24) 24.61 (3.15) 0.058
PD 3.80 (1.63) 3.36 (1.52) <0.001 2.63 (1.02) 2.27 (0.85) <0.001 2.80 (1.11) 2.42 (0.88) <0.001
CAL 4.55 (1.80) 3.97 (1.48) 0.001 3.57 (1.34) 3.06 (1.12) <0.001 3.60 (1.52) 3.13 (1.11) <0.001
BI 66.68 (17.93) 67.33 (15.57) 0.864 22.42 (8.41) 22.81 (10.97) 0.864 27.00 (8.02) 30.50 (9.78) 0.050
PI 54.62 (21.72) 54.63 (21.72) 0.607 18.45 (10.89) 21.49 (14.13) 0.304 30.09 (16.14) 32.78 (14.59) 0.352
BI, bleeding index; CAL, clinical attachment level; SEM, standard error of the mean, PD, probing depth; PI, plaque index.
© 2016 The Authors. Journal of Clinical Periodontology Published by John Wiley & Sons Ltd.
Smoking impairs periodontal treatment 1089
consumption, the serum cotinine
levels were higher for smokers pre-
senting ≥9 sites with PD ≥ 5 mm
with BoP at T2. For this group, the
objectively validated cigarette con-
sumption showed 37.9% higher
mean serum cotinine level at T2
(697 ng/ml) compared with the mean
serum cotinine level in the groups
presenting a lower number of
PD ≥ 5 mm with BoP (433 ng/ml).
At the site level, clinical parame-
ters and numbers of teeth at T0 and
T1 were tested in smokers and non-
smokers as predictors for
PD ≥ 5 mm with BoP at T2
(Table 4). All variables significantly
increased the OR, except for number
of teeth at T0 and T1 and for plaque
positive sites at T0 in smokers. BoP
at T0 was a strong predictor in
smokers (OR: 8.93, CI: 3.28, 24.36,
p < 0.001) and non-smokers (OR:
10.99, CI: 3.33, 36.23 p < 0.001).
Compared with BoP at T0, BoP at
T1 increased the OR in smokers
(OR = 13.26, CI: 5.12, 34.38,
p < 0.001), but not in non-smokers
(OR = 4.68, CI: 1.32, 16.61, p <
0.001). Plaque positive sites at T0
predicted PD ≥ 5 mm with BoP only
in non-smokers (OR = 3.05, CI:
1.19, 7.82, p = 0.020), whereas an
association was revealed between
plaque positive sites at T1 in smok-
ers (OR = 5.83, CI: 2.74, 12.42,
p < 0.001) and non-smokers (OR =
2.29, CI: 1.03, 5.07, p < 0.041).
The overall effect of smoking at
T2 on the number of sites with
PD ≥ 5 mm and BoP was tested at
different teeth and sites using adjusted
logistic regression analysis (Table 5).
An overall negative effect of smoking
was demonstrated (OR = 2.78, CI:
1.49, 5.18, p = 0.001) particularly at
maxillary single-rooted buccal and
palatal sites (OR = 6.21, CI: 2.05,
18.88, p = 0.001 and OR = 4.55, CI:
1.61, 12.85, p = 0.004 respectively),
mandibular single-rooted buccal sites
(OR = 4.35, CI: 1.06, 17.82,
p = 0.041), and mandibular multi-
rooted buccal sites (OR = 4.10, CI:
1.09, 15.38, p = 0.036). The overall
ICC were reported within patients
(ICC = 0.114), teeth (ICC = 0.509),
and sites (ICC = 0.761). The variation
was highest at the patient level and
least at the site level and was consis-
tent within different teeth and sites
(Table 5). At the patient level, the
overall ICC for smokers
(ICC = 0.137) was higher than for
non-smokers (ICC = 0.051; not tabu-
lated).
Discussion
The present study evaluated the
effect of cigarette smoking at
patient, tooth, and site levels follow-
ing 12 months of SPT. During SPT,
smokers and non-smokers presented
increased numbers of PD ≥ 5 mm
with BoP with the greatest increase
at maxillary single-rooted teeth in
smokers; from 10 to 16 at buccal
sites and from 25 to 48 at palatal
sites. An overall negative effect of
smoking was revealed at T2 with the
strongest effect at maxillary single-
rooted teeth. To a great extent, the
site-specific effects explain the out-
comes of periodontal therapy
(D’Aiuto et al. 2005) and the
patient-related effect of smoking
seems to act as a modifier at the
Table 3. Numbers of sites with probing depth ≥5 mm with BoP before (T0), following active (T1), and supportive periodontal therapy (T2)
at arch and tooth level














Overall 1471 (26.4) 1049 (17.5) <0.001 132 (2.6) 52 (1.0) <0.001 180 (3.8) 79 (1.6) 0.001
Maxillary multi-rooted
Buccal 131 (39.7) 136 (32.6) 0.105 10 (3.8) 7 (2.0) 0.209 11 (3.6) 12 (4.6) 0.731
Palatal 175 (53.0) 198 (47.5) 0.309 27 (10.2) 15 (4.2) 0.009 31 (12.0) 21 (6.4) 0.040
Maxillary single-rooted
Buccal 214 (20.8) 124 (11.2) 0.680 16 (1.7) 2 (0.2) 0.121 26 (2.9) 6 (0.6) 0.002
Palatal 374 (46.4) 180 (16.2) 0.030 25 (2.6) 8 (0.8) 0.159 48 (5.4) 12 (1.3) 0.001
Mandibulary multi-rooted
Buccal 99 (33.0) 86 (24.9) 0.269 9 (3.0) 7 (2.3) 0.617 10 (3.4) 3 (1.1) 0.055
Lingual 137 (41.5) 125 (36.2) 0.326 12 (4.0) 9 (2.9) 0.561 17 (5.7) 12 (4.2) 0.473
Mandibulary single-rooted
Buccal 154 (14.1) 95 (8.4) 0.148 14 (1.4) 2 (0.2) 0.628 21 (2.2) 5 (0.5) 0.164
Lingual 187 (17.1) 105 (9.3) 0.011 19 (1.9) 2 (0.2) 0.190 16 (1.7) 8 (0.8) 0.032
BoP; bleeding on probing; multi-rooted, molars; single-rooted, premolars and incisors; buccal, two proximal-buccal and one mid-buccal;

























































Fig. 2. Means of smoking measures in
patients with 0, 1–4, 5–8, and ≥9 sites of
probing depth ≥5 mm and bleeding on
probing at T0 and T2.
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site-specific level. As suggested, the
magnitude of changes during SPT
appears related to the initial defect
size at site level and to heavy smok-
ing at patient level (Matuliene et al.
2008). Moreover, a local effect of
smoking appears to be superimposed
on the systemic effect, particularly
affecting maxillary single-rooted
teeth. In smokers, the percentage of
PD ≥ 5 mm with BoP at these teeth
increased from 31% at T1 to 41% at
T2, whereas the percentage for max-
illary multi-rooted teeth declined
from 28% to 23%, respectively. The
percentage at T2 were comparable
with baseline registration and in
accordance with previous findings
demonstrating a high percentage of
PD ≥ 5 mm in single-rooted teeth in
smokers (van der Weijden et al.
2001). Interestingly, the results show
slightly different site-specific treat-
ment outcomes following APT and
SPT, indicating altered local tissue
responses to cigarette smoking dur-
ing APT compared with SPT.
Including BoP in the primary
outcome variable could introduce a
bias due to less BoP in smokers
compared with non-smokers (Preber
& Bergstr€om 1985, Bergstr€om &
Bostr€om 2001). On the other hand, a
site level periodontal diagnose
including BoP seems to correlate
with disease progression and
periodontal instability irrespective of
smoking status (Ramseier et al.
2015). At a site level, absence of
BoP is considered to predict long-
term stability following treatment of
chronic periodontitis patients (Lang
et al. 1990), whereas presence of
BoP predicts disease progression in
both smokers and non-smokers
(Ramseier et al. 2015). However, it
is not clear whether BoP to the same
extent is associated with disease pro-
gression at a site level in smokers
and non-smokers. In this study, the
association between BoP at T1 and
PD ≥ 5 mm with BoP at T2 was
stronger in smokers compared with
non-smokers. More intense bleeding
from deep pockets following non-
surgical periodontal therapy in
smokers (Ardais et al. 2014) can be
explained by a hyper-inflammatory
condition in gingival tissues, thus
making BoP a strong predictor for
disease progression during SPT.
A tendency towards recurrence of
periodontitis during SPT was sup-
ported by a significant increase in
PD, BI, and PI in both smokers and
non-smokers. These findings are in
agreement with previous studies
showing a slight disease progression
during the first years following ATP
(Knowles et al. 1979, Preshaw &
Heasman 2005). These longitudinal
trends of treatment progression
might reflect lack of compliance
from highly susceptible patients dur-
ing the first years of SPT. In this
study, to compensate for variation in
compliance among smokers
Table 4. Clinical parameters and number of teeth as predictors for probing depth (PD) ≥ 5 mm with bleeding on probing (BoP) at T2 in
smokers and non-smokers
Smokers Non-smokers
OR (95% CI)a p OR (95% CI)a p
T0
Teeth 1.02 (0.94, 1.10) 0.699 1.16 (1.01, 1.34) 0.035
CAL 1.48 (1.19, 1.83) <0.001 1.63 (1.32, 2.02) <0.001
PD 2.12 (1.74, 2.59) <0.001 2.25 (1.68, 3.01) <0.001
BoP 8.93 (3.28, 24.36) <0.001 10.99 (3.33, 36.23) <0.001
Plaque 2.21 (0.70, 6.36) 0.185 3.05 (1.19, 7.82) 0.020
T1
Teeth 1.03 (0.94, 1.12) 0.527 1.16 (1.03, 1.31) 0.017
CAL 2.25 (1.80, 2.82) <0.001 2.81 (2.14, 3.67) <0.001
PD 5.63 (3.46, 9.16) <0.001 7.39 (4.25, 12.85) <0.001
BoP 13.26 (5.12, 34.38) <0.001 4.68 (1.32, 16.61) <0.001
Plaque 5.83 (2.74, 12.42) <0.001 2.29 (1.03, 5.07) 0.041
T0-T2, baseline before active periodontal therapy (T0)-12 months of supportive periodontal therapy (T2), T1-T2; following completion of
active periodontal therapy (T1)-12 months with supportive periodontal therapy (T2).
aLogistic regression showing effect of tooth and site-related conditions at T0 and at T1 adjusted for gender, age, marital status, and education.
Table 5. The effect of smoking on probing depth ≥5 mm with bleeding on probing at T2
presented with intra-class correlation coefficients (ICC) within patients, teeth, and sites
OR (95% CI) p ICCa ICCb ICCc
Overall 2.78 (1.49, 5.18) 0.001 0.114 0.509 0.761
Maxillary multi-rooted 1.55 (0.74, 3.23) 0.238 0.165 0.472 0.758
Buccal sites 1.12 (0.46, 2.75) 0.802 0.161 0.286 0.686
Palatal sites 1.81 (0.84, 3.88) 0.129 0.182 0.371 0.746
Maxillary single-rooted 5.08 (2.01, 12.78) 0.001 0.184 0.476 0.752
Buccal sites 6.21 (2.05, 18.88) 0.001 0.156 0.351 0.754
Palatal sites 4.55 (1.61, 12.85) 0.004 0.210 0.406 0.733
Mandibular multi-rooted 2.51 (1.01, 6.23) 0.047 0.163 0.355 0.691
Buccal sites 4.10 (1.09, 15.38) 0.036 na 0.117 0.746
Lingual sites 2.12 (0.82, 5.49) 0.120 0.168 0.231 0.642
Mandibular single-rooted 3.09 (1.01, 9.43) 0.048 0.171 0.575 0.763
Buccal sites 2.34 (0.75, 7.26) 0.143 0.257 0.401 0.755
Lingual sites 4.35 (1.06, 17.82) 0.041 0.136 0.664 0.781
Logistic regression showing main effect of patient-related conditions at T2 adjusted for gen-
der, age, marital status, and education.
aICC, intra-class correlation coefficients within patients.
bICC, intra-class correlation coefficients within teeth.
cICC, intra-class correlation coefficients within sites na; not available.
© 2016 The Authors. Journal of Clinical Periodontology Published by John Wiley & Sons Ltd.
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(Ramseier et al. 2014), a 3-month
SPT frequency compatible with
maintenance of highly susceptible
patients, was offered. Preferably, the
frequency of SPT should reflect the
individual risk profile. However, in
this prospective study, the SPT inter-
val was standardized regardless of
the susceptibility for recurrence of
periodontitis, and patients exceeding
a 4-month interval were excluded.
The effort to adjust for compliance
should be considered a merit in the
analyses of evaluating the effect of
smoking exposure on the efficacy of
SPT.
The exposure of smoking was
quantified and objectively validated
by measuring serum cotinine concen-
tration. At T2, an association was
revealed between ≥9 sites of
PD ≥ 5 mm with BoP per patient
and high cotinine levels. Heavy
smoking during periodontal treat-
ment, quantified by high levels of
cotinine, negatively influenced the
outcome of SPT. This association
was not detected at T0, indicating
that doses of current smoking expo-
sure do not to the same extent influ-
ence the level of periodontal disease.
Consequently, when smoking cessa-
tion is not successful, reduced smok-
ing exposure during therapy should
be encouraged. A dose-related treat-
ment response has been documented
(Kaldahl et al. 1996a), however, not
by objective measures of smoking
exposure during therapy. In this
study, 86% of the patients with ≥9
sites of PD ≥ 5 mm with BoP at T2
were heavy smokers. These findings
are in agreement with a former study
concluding that 90% of non-respon-
ders are smokers (Magnusson &
Walker 1996). Non-responding peri-
odontitis, characterized by multiple
progressing sites following therapy,
is considered a patient-specific more
than site-specific entity. Smoking as
a patient-related risk factor has pre-
viously been recognized (Kornman
et al. 1997, Matuliene et al. 2010)
and in this study, smoking out-
weighed other patient-related risk
factors documented by a smaller
variation in PD ≥ 5 mm with BoP at
T2 within smokers compared with
non-smokers.
A few limitations of this study,
however, should be discussed. The
lack of masking has been addressed
previously (Bunæs et al. 2015).
Further, a follow-up period of
12 months is a relatively short time
to study the effect of smoking on
the outcome of SPT. An extension
of the observation period might pro-
vide more substantiated information.
On the other hand, during a longer
follow-up period, more patients are
prone to drop out and a higher
number of smokers might quit
smoking. Both factors could defi-
nitely have undermined the statisti-
cal analysis and the validity of the
results. Three smokers reported
smoking cessation between T1 and
T2 and yet were not excluded from
the study. Matching serum cotinine
concentration confirmed smoking
cessation for one, whereas the other
two reported the use of snuff to sub-
stitute cigarette nicotine. In Scandi-
navia, the use of snuff has increased
significantly during recent years,
especially among adolescents (Her-
gens et al. 2014). Unregistered use
of snuff may have disturbed the
measured cotinine concentrations in
serum and might be considered a
confounder.
In summary, both smokers and
non-smokers showed a slight recur-
rence of disease following
12 months of SPT. However, both
smokers and non-smokers
responded to periodontal therapy
with significant reductions in mean
PD, CAL, BI, and PI (p < 0.001).
An overall negative effect of smok-
ing on PD ≥ 5 mm with BoP was
demonstrated with a site-specific tis-
sue response to smoking. Further,
BoP at T1 in smokers was a strong
site-specific predictor for
PD ≥ 5 mm with BoP at T2. At the
patient level, elevated cotinine mea-
sures at T2 were associated with ≥9
sites of PD ≥ 5 mm with BoP. The
study reveals that cigarette smoking
as a patient-related risk factor may
modulate site-associated variables
affecting outcomes of SPT. The
magnitude of the effect of cigarette
smoking on local tissue responses
should be further explored in
prospective studies with objective
quantification of smoking exposure.
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Scientific rationale for the study: In
general, smokers respond less
favourably to periodontal therapy
compared with non-smokers. To
predict the long-term outcome of
periodontal therapy in smokers,
the effect of smoking needs to be
evaluated at patient, tooth, and site
level following active therapy.
Principal findings: An overall nega-
tive effect of smoking was demon-
strated following 12 months of
supportive periodontal therapy,
especially at maxillary single-rooted
teeth. At patient level, high serum
cotinine levels were associated with
≥9 disease progressing sites. At site
level, bleeding on probing following
active periodontal therapy predicted
an increased risk of disease pro-
gression in smokers compared with
non-smokers.
Practical implications: In perspec-
tive, smoking cessation or even
smoking reduction may benefit
treatment outcomes following sup-
portive periodontal therapy.
© 2016 The Authors. Journal of Clinical Periodontology Published by John Wiley & Sons Ltd.
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Background and Objective: Periodontal health is mediated by supressing 
microorganisms inducing a local inflammatory host response. Smoking may impair 
this process. This study compares gingival crevicular fluid levels of inflammatory and 
bone remodelling markers in heavy smokers and non-smokers following active and 
supportive periodontal therapy in chronic periodontitis patients.   
Materials and Methods: Gingival crevicular fluid (GCF) and subgingival plaque 
were collected from the deepest periodontal pocket in 50 patients, 25 smokers and 25 
non-smokers, at baseline (T0), following active (T1) and 12 months of supportive 
periodontal therapy (T2). Smoking status was validated measuring serum cotinine 
levels. GCF levels of 27 inflammatory and two bone remodelling markers were 
analysed using multiplex and singleplex micro-bed immunoassays, and subgingival 
plaque samples using checkerboard DNA-DNA hybridization. Amounts of markers in 
smokers and non-smokers were compared calculating the effect size.  
Results: Expression of inflammatory and bone-remodeling markers in smokers 
demonstrated an overall reduced effect size at T0 and T2 (p<0.001) More specifically, 
pro-inflammatory markers (p<0.001), chemokines (p=0.007) and growth-factors 
(p=0.003) at T0, osteoprotegerin (p=0.003) at T1, pro-inflammatory markers 
(p=0.019) and chemokines (p=0.005) at T2. At T2, IL-8 was detected in significantly 
higher levels in smokers. Ten different markers in non-smokers and none in smokers 
responded to periodontal therapy (p<0.05). An overall negative association was 
revealed between smoking and sub-groups of markers at sites presenting ≥105 red 
complex periodontal microbial species. 
Conclusion: Except for an upregulation of IL-8, smokers exhibited reduced GCF 
levels of several inflammatory markers at baseline and following active and supportive 
periodontal therapy.  Only inflammatory responses in non-smokers adapted to 
periodontal therapy. Apparently, there seems to be an immunosuppressant effect of 
smoking regulating the local inflammatory response and bone remodelling markers 






Cigarette smoking may affect periodontal tissues through modulating the immune 
response to periodontal pathogens. A dose-dependent hypo-immune inflammatory 
reaction has been suggested, mainly through systemic exposure following lung 
absorption (1-3). An additive local effect of smoking through direct exposure and 
absorption of toxic substances may adversely shift the periodontal equilibrium towards 
impaired repair and tissue breakdown (4, 5). Further, differences exist in composition 
of subgingival microbiota among smokers and non-smokers (6). Moreover, smoking 
appears to modulate composition, promote colonization of key periodontal pathogens, 
and influence bacterial aggregation (7, 8) rather than rate and amount of plaque 
accumulation (9, 10). 
Periodontal pathogens induce release of inflammatory and bone remodelling 
markers orchestrating innate and adaptive immune responses. The interaction and 
balance of these markers determine whether the tissue response remains stable or leads 
to destruction and disease progression (11). Gingival crevicular fluid (GCF), an 
inflammatory exudate or transudate collected from the gingival crevice, contains 
components of host-derived inflammatory markers (12). Thus, GCF analysis appears a 
non-invasive approach to investigate site-specific inflammatory responses and assess 
presence of various inflammatory markers (13). In smokers, site-specific tissue 
responses are clinically expressed by a specific attachment loss profile (14). However, 
site-specific mapping of inflammatory and bone-remodelling markers in smokers with 
chronic periodontitis reports conflicting results (15). A majority of studies have 
reported decreased local expression of some pro-inflammatory cytokines and 
chemokines in smokers (16-18) indicating an immunosuppressant effect of smoking 
that may increase susceptibility to periodontitis. Conversely, elevated expressions of 
chemokines and pro-inflammatory cytokines have also been reported in smokers (19, 
20). For bone remodelling, decreased GCF levels of osteoprotegerin (OPG) have been 
demonstrated following ≥20 years of smoking (21). As OPG blocks activation of 
receptor activator for nuclear factor kappa-B ligand (RANKL), the RANKL:OPG 
ratio, a surrogate marker for periodontal bone homeostasis, might increase in smokers 





Compromised healing following periodontal therapy in smokers is well 
documented (22-24) and impaired site-specific treatment outcomes may to some extent 
be explained by altered inflammatory responses (25). A few prospective studies have 
investigated the relationship between smoking and levels of pro-inflammatory 
markers, chemokines, and bone markers in GCF following periodontal therapy. IL-1β 
and TNF-α, are mostly studied; IL-1β levels decreased in smokers and non-smokers 
following 6 weeks of non-surgical therapy (26), whereas at 6 months the levels were 
reduced in non-smokers only (27). TNF-α did not change in smokers and non-smokers 
following 1 month of non-surgical therapy (28). At 6 months, however, a decreased 
level was observed in smokers (29). Interestingly, smoking seemed to upregulate the 
chemokine IL-8 following therapy (30), whereas OPG decreased in both smokers and 
non-smokers (31).   
Previous follow-up studies evaluating the local inflammatory status, have 
analysed a limited number of GCF markers. Multiplex immunoassay has the potential 
to simultaneously quantify multiple markers providing unique information necessary 
for a more complex understanding of the inflammatory response. By measuring 
several inflammatory markers over time, a site-specific tissue response to periodontal 
therapy can be monitored. Thus far, no prospective study has compared inflammatory 
responses in GCF following active and supportive periodontal therapy in smokers and 
non-smokers.  
This prospective study was designed to test the hypothesis that smoking 
downregulates the expression of the inflammatory molecules in GCF during treatment 
of chronic periodontitis. The primary aim was to investigate the GCF levels of 
inflammatory markers involved in periodontal inflammation and healing following 
active and 12 months of supportive periodontal therapy in heavy smokers and non-
smokers. The impact of smoking on the numbers of subgingival periopathogens 






MATERIAL AND METHODS 
Participants and study design  
From a sample of 80 patients, 40 smokers and 40 non-smokers, referred for 
periodontal treatment from general practitioners in a rural district of Norway, a 
subsample of  50 patients were enrolled in this single-arm clinical trial (for detail see 
Bunæs et al. 2015;(24). Briefly, criteria for inclusion were healthy subjects between 
35-75 years with moderate to severe chronic periodontitis (32) having at least four 
non-adjacent teeth with interproximal probing depth (PD) ≥6 mm, clinical attachment 
loss ≥5 mm, and bleeding on probing (BoP) (33, 34). Exclusion criteria were any 
current medical condition or medication affecting periodontal treatment and the use of 
systemic antibiotic or subgingival scaling in the 6 months before initiation of the 
study. Demographic data were obtained from the study participants by means of health 
forms and questionnaires. 
Based on predefined criteria, the 50 patients were allocated into two subgroups 
of 25 smokers reporting smoking >10 cigarettes/day for at least 5 years and with 
baseline pre-treatment (T0) serum cotinine level ≥300 ng/mL, and 25 non-smokers 
reporting never or no smoking the last 5 years and with T0 serum cotinine level ˂15 
ng/ml. Whole blood sample obtained from each patient was coagulated and 
centrifuged (700 x g for 10 min) and the serum was stored in aliquots at -80°C. Serum 
cotinine was assessed according to the manufacturer’s instructions of the serum 
enzyme immunoassay kit (Cotinine ELISA Kit, MyBioSource, San Diego, USA) 
measuring the absorbance at 450 nm using a microplate reader (FluoStar Optima 
V1.32 R2, BMG Labtech, Offenburg, Germany). 
The study protocol and informed consent form was approved by the 
Institutional Medical Research Ethics Committee (2011/151-6), University of Bergen, 
Norway followed the Helsinki Declaration of 1975, version 2008. All patients had read 
and signed a written consent prior to enrolment in the study. 
Clinical and microbiological examinations 
Clinical assessments, group allocations, and sampling selection were performed by a 
calibrated examiner (DFB). Clinical and microbiological sample collection were 





(T1), and following 12 months of supportive periodontal therapy (SPT) (T2). Mean 
time between T0 and T1 was 7.9 months and comprised non-surgical and surgical 
treatment. Patients presenting persistent PD >5 mm with BoP and adequate oral 
hygiene following non-surgical treatment were subjected to periodontal surgery. SPT 
was conducted every 3 months. PDs were recorded as the distance in mm from the 
gingival margin to the probeable base of the periodontal pocket, and clinical 
attachment level (CAL) as the distance in mm from the cemento-enamel junction or 
the margin of a dental restoration to the probeable base of the periodontal pocket. PD 
and CAL were measured using a periodontal probe (PCPUNC 15, Hu-Friedy, Chicago, 
IL, USA) at six sites per tooth rounding up to the nearest mm. Full mouth gingival 
bleeding was recorded as the percentage of sites showing bleeding after gentle probing 
(35) and full mouth dental plaque as the percentage of tooth surfaces with visible 
plaque following staining with disclosing solution (36). As a supplement to staining, 
the periodontal probe was used to discriminate between plaque and pellicle.  
At T0 subgingival plaque were collected by inserting two sterile paper points into the 
deepest periodontal pocket in each patient, and the procedure was repeated at the same 
site at T1 and T2. Prior to sampling, the site was carefully cleaned of supragingival 
plaque and kept dry. The paper points were gently inserted towards the apex of the 
pocket and kept in place for 20 sec (37) before removal and immersion into a pre-
reproduced sterile transport medium (PRAS Dental Transport Medium, Morgan Hill, 
CA,USA). The microbiological samples were analysed by DNA-DNA hybridization 
(checkerboard technique) at Microbiological Diagnostic Service, Department of Oral 
Biology, Faculty of Dentistry, University of Oslo, Oslo, Norway. The analysis 
included detection and quantification of red (Porphyromonas ginigvalis, Taneralla 
forsythia, and Treponema denticola) and orange complex species (Prevotella 
intermedia, Prevotella nigrescens, Fusobacterium nucleatum subsp polymorphum, 
Fusobacterium nucleatum subsp nucleatum, Fusobacterium nucleatum subsp vincentii, 
and Parvimonas micra), and Aggregatibacter actinomycetemcomitans (Aa) (for details 
see Bunæs et al., 2015; (24).   
 Intra-examiner reliability of the examiner (DFB) was assessed using the 





0.92 and 0.96 for PD and between 0.93 and 0.96 for CAL. A post.hoc power analysis 
based on 25 heavy smokers and 25 non-smokers and with the level of significance (α) 
set to 0.05, gave a 71% power to detect a true difference of 0.5 mm. Prior to treatment, 
the hypothesis that is not possible to blind an examiner towards smoking status was 
tested in a pre-study sample of 30 chronic periodontitis patients, 16 smokers (>10 
cigarettes/day for at least 5 years) and 14 non-smokers (never or not in the last 5 
years). Calculus, plaque, and staining were removed and after rinsing with 0.2% 
chlorhexidine gluconate (Corsodyl, GlaxoSmithKline, London, UK) for 1 min, the 
examiner wearing a face mask scored the smoking status as yes or no. Twenty-eight 
patients (93%) were correctly identified as either non-smokers or smokers. Thus, the 
pre-study hypothesis was accepted (p<0.001) indicating that the attempt to blind the 
examiner with regard to smoking status was unsuccessful. 
GCF sampling and protein extraction 
GCF samples were collected using Periopaper strips, (PERIOPAPER Gingival Fluid 
Collection Strips, Oraflow Inc, Smithtown, NY, USA). Following removal of 
supragingival plaque with sterile curettes and cotton pellets, air dried, and isolated 
with cotton rolls, the deepest periodontal pocket in each participant was sampled. The 
paper strips were placed 1-2 mm into the entrance of the pocket and left in place for 30 
sec. Strips visually contaminated with blood or saliva were discarded. Sampled strips 
were immediately evaluated for GCF volume using the Periotron 8000 (Oraflow Inc, 
Smithtown, NY, USA). Strips were then immediately inserted into separate and dry 
microtubes, labelled, and stored at -80°C until further analysis.  
Tris-HCl buffer (110 μL) with a final concentration of 12mM at pH 7.6 was 
added to each tube for protein extraction. The tubes were shaken in 3x10 min before 
centrifuged (1800 x g for 10 min at 4°C) and subsequently the supernatant was 
pipetted to new tubes for protein quantification by a commercially available kit 
(Pierce™ BCA Protein Assay Kit, Thermo Scientific, Rockford, IL, USA). A plate 
reader (FLUOstar OPTIMA- BMG Labtech, Ortenberg, Germany) measured the 





Analysed markers  
Based on inflammatory and bone remodeling molecules involved in the periodontal 
healing process , the following cytokines were determined (diluted 1:4) using the 
multiplex kit Bio-Plex Human ProTM Assay (catalogue number LX10009222405) from 
Bio-Rad Inc., Hercules, CA, USA: IL-1β, IL-2, IL-1ra, IL-4, IL-5, IL-6, IL-7, IL-8, IL-
9, IL-10, IL-12, IL-13, IL-15, IL-17, Interferon-γ (IFN-γ), Basic Fibroblast Growth 
Factor (FGF), Granulocyte Colony Stimulating Factor (G-CSF), Eotaxin , 
Granulocyte-Monocyte Colony Stimulating Factor (GM-CSF), Interferon Inducible 
Protein-10 (IP-10), Monocyte Chemo-attractive Protein-1 (MCP-1), Macrophage 
Inflammatory Protein-1α (MIP-1α), Macrophage Inflammatory Protein-1β (MIP-1β), 
Platelet-Derived Growth Factor (PDGF), Regulated Upon Activation, Normally T-
Expressed, and Presumably Secreted (RANTES), Tumor Necrosis Factor-α (TNF-α) 
and Vascular Endothelial Growth Factor (VEGF). The standard curves for each 
marker present an overall range of 107489-0.064 pg/mL. 
The level of OPG and RANKL were assessed (diluted 1:4) using Milliplex MAP 
Kit Human Bone Magnetic Bead Panel (catalogue number HRNKLMAG-51K-01) 
from EMD Millipore corp. (Billerica, MA,USA) and a range of 30367-7.28 pg/mL 
recombinant markers was used to establish the standard curves. 
All measurements were performed using a Bio-plex 200®system (Bio-Plex 
Manager TM 6 software) based on the Luminex xMAP technology and the levels of all 
markers were reported in pg/30 sec and in pg/ml. 
Statistical analysis 
The Shapiro-Wilk test was applied to test for distribution of continuous variables. 
Descriptive statistics of clinical and demographical data were analysed using a chi-
square test for categorical variables (frequencies and percentages) and by a two-
sample independent t-test for continuous data (mean ± SD). As continuous data of the 
analysed mediators had a skewed distribution, natural logarithm transformation was 
employed to achieve normality prior to using the regression analysis to detect 
differences between smokers and non-smokers at T0, T1, and T2 and over time (T0 vs. 
T1, T0 vs. T2, and T1 vs. T2). Samples below detection of the standard curve were 





corrected for clustering of data within patients and the significance level of multiple 
comparisons were adjusted by the Sidak post-hoc test. A regression model, adjusted 
for age, gender, and education, and stratified by plaque (present/absent) or amount of 
red complex bacteria species (<105 / ≥105) was employed to test the overall association 
between the subgroups of quantified markers and smoking status.  
Amounts markers (pg/30 sec) in smokers and non-smokers were compared by 
calculating the effect size. Effect size, reported as Cohens`s coefficient, was calculated 
as the difference between the means of each marker in smokers and non-smokers 
divided by the standard deviations. Cohen`s coefficient is generally classified into 
small (0.2), medium (0.5), and large differences (≥0.8) and allows the size magnitude 
of the difference between smokers and non-smokers to be measured in a standardised 
scale. To present the results, forest-plots for the standardised effects sizes were used. 
An overall test of the difference between markers in smokers and non-smokers were 
analysed using fixed effects in the metan command (39).   
A p-value ≤0.05 was considered statistically significant. All analyses were 
conducted using Stata 14 (Stata Statistical Software: Release 14. StataCorp LP, 
College Station, TX, USA). 
 
RESULTS 
A total of 50 patients were evaluated, 25 smokers and 25 non-smokers. At T0, mean 
pack-year consumption in the smoking group was 37.0 (range 20-108) and mean 
cotinine level 478 mg/mL (range 340-861 mg/mL). For each patient, GCF samples 
were obtained from the same site at T0, T1, and T2. Data collection started April 2012 
and ended December 2014. Baseline patient related clinical and demographic 
characteristics according to smoking status are shown in Table 1. Compared with non-
smokers, significantly lower education level, higher mean PD and CAL were found for 
smokers. Mean patient related clinical measures of PD, CAL, BI, and PI, decreased 
significantly following ACT in smokers and non-smokers (p<0.001) and PD, BI, and 
PI increased significantly following SPT (p<0.05). Site-specific clinical and 
microbiological characteristics at T0, T1, and T2 are summarised in Table 2. No 





site-specific parameter at any time point, except for significantly higher numbers of Aa 
in non-smokers compared with smokers at T0 (p=0.041). 
GCF markers detected in less than 30% of the samples (IL-2, IL-5, IL-12, IL-
13, IL-15, Eotaxin, FGF, MCP-1 and RANKL) were removed from the analysis. The 
surveyed markers at T0, T1, and T2 were stratified by smoking status and comparisons 
of unadjusted means of the quantities are presented as amounts per 30 sec (pg/30sec) 
(Table 3a) and as concentrations (pg/mL) (Table 3b). Further analyses were conducted 
on the amounts of markers per 30 sec (40). Compared with non-smokers, significant 
lower levels were detected in smokers for TNF-α, IL-9, G-CSF, GM-CSF, IFN- γ, 
VEGF, MIP-1α and RANTES at T0, for OPG at T1, and for IL-9, IFN- γ, PDGF, MIP-
1α, MIP-1β, RANTES at T2. At T2, IL-8 was detected in significantly higher levels in 
smokers (p=0.034). Only non-smokers responded to treatment with significant changes 
in surveyed markers over time. From T0 to T1, significant reductions were revealed 
for IL-1β, TNF-α, IL-7, GM-CSF, IFN-γ, IL-10, VEGF and IP-10, and from T0 to T2 
for IL-1β and GM-CSF. A significant upregulation of TNF-α, IL-7, IL-9, IFN-γ, IL-
10, PDGF, and IP-10 was observed from T1 to T2. 
Based on the biological effects, the markers were distributed into subgroups of 
pro-inflammatory markers (IL-1β, IL-6, IL-9, IL-12 and TNF-α), anti-inflammatory 
markers (IL-4 and IL-10), chemokines (IL-8, IP-10, MCP-1, MIP-1α, MIP-1β and 
RANTES), growth factors (PDGF and VEGF), Th-1/Th-2 (INF-γ/ (IL-4, IL-6, IL-9, 
IL-10), and marker of bone remodelling (OPG). Since the markers were expressed in 
various amounts in smokers and non-smokers and measured in different scales 
(range107489-0.064), the magnitude of the differences between smokers and non-
smokers was calculated as effect size (Cohen`s coefficient). Figure 1a, b and c 
illustrate the size of the effect of smoking on the expression of marker and subgroup at 
T0, T1, and T2, respectively. At T0 smoking significantly reduced effect size for pro-
inflammatory markers (p=0.001), chemokines (p=0.007), and growth-factors 
(p=0.003), at T1 for OPG (p=0.003), and at T2 for pro-inflammatory markers 
(p=0.019) and chemokines (p=0.005). 
The subgroups were tested for overall association with smoking status after 





(<105/≥ 105) (Table 4). The numbers of tested sites in the analysis are not tabulated: 
plaque positive sites [n=96 (45 smokers / 51 non-smokers)], plaque negative sites 
[n=54 (30 smokers / 24 non-smokers], red complex positive sites [n=49 (23 smokers / 
26 non-smokers)], and red complex negative sites [n=101 (52 smokers / 49 non-
smokers)]. At plaque positive sites, a significant negative association with smoking 
status was revealed for pro-inflammatory markers, chemokines, and growth factors. 
For each group, adjusted analyses demonstrated an overall significant negative 
association with smoking status for plaque positive sites and an overall positive 
association for plaque negative sites. Further, in both unadjusted and adjusted 
analyses, negative associations were revealed between smoking status and groups of 
pro- and anti-inflammatory markers and OPG at sites presenting ≥105 red complex 
species. No significant associations were detected between smoking and groups of 
markers at sites presenting < 105 red complex species. The same tests were performed 
for orange complex species and Aa and a significant negative association between 
smoking and amounts of pro-inflammatory markers were only present for the adjusted 
analysis of sites < 105 orange complex species (p=0.033) (not tabulated). 
 
DISCUSSION 
Significantly smaller amounts of several inflammatory markers were detected in 
smokers compared with non-smokers at T0 and in the presence of increased clinical 
inflammation from T1 to T2. The expression of GCF markers at a site might be 
influenced by mean levels of PD and CAL (41). Sampling from the deepest PD in 
smokers and non-smokers rather from matched PD could have biased the analyses. 
However, the reliability of an overall reduced inflammatory response in smokers was 
substantiated by the fact that GCF samples were collected from sites exhibiting similar 
PD, CAL, BI, PI, and GCF volume in smokers and non-smokers. Another 
methodological concern when including smokers in clinical studies is the unsuccessful 
blinding of the examiner with regard to smoking status. This might in fact introduce a 
study bias. Further, strict sampling procedures and a trained operator intended to 
prevent a potential saliva contamination of the periopaper strips during the GCF 





An overall suppressed inflammatory response in smokers is supported by 
Tymkiw and suggests a local hypo-inflammatory state in smokers with chronic 
periodontitis (17). Reduction of important pro-inflammatory cytokines may initially 
alter local cytokine regulated inflammatory processes and persuade a dysfunctional 
response to stimuli such as bacterial lipopolysaccharides. In smokers at T0, significant 
reduced amounts of TNF-α, a multifunctional pro-inflammatory cytokine promoting 
cell migration and tissue destruction, might downregulate IL-1β and IL-6 and reduce 
production of chemokines (42). Though investigations of the impact of smoking on the 
expression of chemokines are limited, reduced amounts of chemokines in smokers 
have been confirmed by others (17, 43). In the present study, the slight rebound of 
periodontal disease during SPT coincided with increased amounts of MIP-1α, MIP-1β 
and RANTES at T2 in non-smokers only. As these chemokines facilitate migration 
and activation of specific types of leukocytes in response to periodontal pathogens 
(44), a downregulation of chemokines in smokers might reduce recruitment of 
inflammatory cells into infection sites. Chemokines also stimulate bone remodelling 
driving osteoblast migration (45) and reduced expression might negatively influence 
bone metabolism. A negative impact of smoking on bone homeostasis might be further 
supported by lower levels of OPG in smokers compared with non-smokers (significant 
at T1). RANKL was not detectable and an influence of smoking on the RANKL:OPG 
ratio can only be speculated upon. Nevertheless, increased bone loss in smokers with 
chronic periodontitis could be attributed to decrease in OPG and a subsequent increase 
in the RANKL:OPG ratio with a potential stimulation of osteoclasts. Another study in 
periodontitis patients with varying smoking status has reported reduced GCF levels of 
OPG in high pack-years consumption groups compared with non-smokers (21). 
IL-8 was the only inflammatory marker detected in significantly higher amounts 
in smokers compared with non-smokers. This is in agreement with previous studies 
(18, 20) indicating that smoking seems to upregulate the expression of IL-8 in a dose 
dependent manner (46). IL-8 is a chemokine associated with subclinical inflammation 
of initial periodontal lesions through migration of polymorphonuclear neutrophils 
(PMNs) to the infection sites (47, 48). Modulated inflammatory responses in smokers 





in smokers may increase chemotaxis and migration of dysfunctional PMN cells. 
Moreover, IL-8 has an important role in bone metabolism with direct actions on 
osteoclast activity and differentiation (50). Since IL-8 is suggested to play a crucial 
role in the pathogenesis of chronic periodontitis, an upregulation of IL-8 production in 
smokers might be a detrimental factor for impaired treatment outcome and recurrence 
of periodontal disease, especially in heavy smokers. 
None of the analysed inflammatory and bone remodelling markers responded 
significantly to treatment in smokers. This may strengthen the perception that smoking 
has a capacity to overwhelm and suppress local inflammatory response to periodontal 
pathogens (17, 51).  Non-smokers responded to treatment with changes in the amounts 
of inflammatory markers reflecting positive treatment responses and for several 
markers a significant reduction was observed from T0 to T1 followed by an increase 
from T1 to T2. The amounts of three principal pro-inflammatory markers, IL-1β, TNF-
α, and IFN-γ, reduced significantly as a response to therapy. INF-γ is related to Th-1 
response and inhibition containment of periodontal infection by enhancing phagocytic 
activity of macrophages and neutrophils(52), whereas IL-1β and TNF-α are the first 
markers emerging during the periodontal inflammation processes. IL-1β is a major 
mediator for periodontal disease and involved in inflammatory cell migration and 
osteoclastogenesis (53). Another longitudinal study reported  significant reduction of 
IL-1β  at 4 months following non-surgical periodontal therapy, supporting present 
findings  of a sustained decrease in IL-1β following treatment in non-smokers (47, 54). 
A persistent release of pro-inflammatory cytokines in smokers following active and 
supportive periodontal therapy may partially be explained by impaired resolution of 
inflammation and recurrence of periodontal disease following therapy.  
As a response to active periodontal therapy, all clinical parameters improved 
significantly in smokers and non-smokers whereas the total numbers of red complex 
species, Porphyromonas gingivalis, Tannerella forsythia, and Treponema denticola, 
were significantly reduced in non-smokers only. The non-significant reduction of red 
complex species observed between T0 and T1 in smokers, could stimulate local 
inflammatory responses maintaining elevated amounts of GCF markers at T1. 





aggravation of the biofilm and delayed reduction of red complex species in smokers 
following ATP. Nevertheless, following SPT, a significant reduction of total red 
complex species took place in smokers without significant changes in the amounts of 
inflammatory markers. A dysregulated inflammatory response to periopathogenic 
bacteria in smokers was further supported by negative associations between smoking 
and groups of inflammatory markers at plaque positive sites and at sites harbouring 
≥105 of red complex species. It would be of interest to investigate the plaque with 
high-through put techniques, whereas DNA-DNA checkerboard hybridization 
technique has a rather crude accuracy.  Keystone pathogens other than P Gingivalis 
may be determined for host response in smokers and Parvimonas Mirca is considered 
a keystone pathogen associated with deep pockets in smokers (7, 55). Nevertheless, 
the majority of immune responses to periopathogens are known to occur locally within 
the periodontal tissues, in GCF, and between cells conjugated to another, rather than to 
systemic responses (56, 57). However, in smokers, the amounts of inflammatory 
markers appeared to be modulated not only by site-specific factors as presence of 
plaque and a high number of red-complex species, but also by the complex systemic 
influence of cigarette smoke.  
In general, expressed markers in GCF using multiplex assays and ELISA`s are 
detected with similar trends, but not directly comparable due to methodological 
variations (58), varying amounts of markers, and measurements at different scales. 
Two recent reviews support reporting of total marker content per 30 sec, especially for 
longitudinal studies, together with smoking status, and clinical parameters at collection 
sites (40, 53). They argue that low levels of gingival crevicular fluid volumes 
following periodontal therapy can negatively influence calculation of the 
concentration. Reduced GCF and BoP in smokers compared with non-smokers (59, 
60) , could be an explanation for the suppressed response and downregulation of 
markers collected per 30 sec in smokers. Related to progression of chronic 
periodontitis, it appears to be an association between BoP in both smokers and non-
smokers (3, 61). Nevertheless, GCF volume did not vary significantly between 
smokers and non-smokers and analysis with concentrations of markers reported the 





differences in the amounts among markers are standardized and forest plots illustrate 
the magnitude of the difference between smokers and non-smokers. Further, non-
pooled samples and an objective validation of smoking status, reduced the number of 
confounding factors in the comparisons of GCF markers following periodontal therapy 
in smokers and non-smokers and to some extent weight up for the relatively low 
sample size. 
The results herein confirmed the study hypothesis by a suppressed 
inflammatory reaction presented as reduced expression of GCF markers in heavy 
smokers, especially for pro-inflammatory markers and chemokines. Furthermore, 
smokers did not respond to periodontal therapy with significant changes in the 
amounts of any marker in GCF and a negative association was detected between 
smoking and expression of markers at plaque positive sites. Future prospective studies 
should contextualize the local tissue responses in smokers within the influence of a 
larger systemic effect of smoking.  
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a. Forest plot for overall standardized effect of smoking at T0 for markers in GCF. 
b. Forest plot for overall standardized effect of smoking at T1 for markers in GCF.  












Table 1. Baseline patient related characteristics, presented as mean 





Male1 32 % (8)  52 % (13) 0.158 
Elementary school (≤ 9 years)1 76  % (19)  36 % (9) 0.004 
Age2 56.6 (2.07)  57.9 (1.86) 0.658 
Body mass index2 22.9 (1.32)  23.62 (1.69) 0.742 
Number of teeth2 23.5 (1.19)  25.8 (0.48) 0.076 
Probing depth2 3.9 (0.12)  3.3 (0.10) 0.001 
Clinical attachment level2 4.6 (0.19)  4.0 (0.11) 0.008 
Bleeding index2 69.7 (4.00)  66.5 (3.06) 0.532 
Plaque index2 51.6 (3.96)  56.3 (3.78)  0.415 
1 chi-square test 
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